array:24 [
  "pii" => "S2254887417301285"
  "issn" => "22548874"
  "doi" => "10.1016/j.rceng.2017.07.005"
  "estado" => "S300"
  "fechaPublicacion" => "2018-01-01"
  "aid" => "1421"
  "copyright" => "Elsevier España, S.L.U. and Sociedad Española de Medicina Interna (SEMI)"
  "copyrightAnyo" => "2017"
  "documento" => "article"
  "crossmark" => 1
  "subdocumento" => "ssu"
  "cita" => "Rev Clin Esp. 2018;218:29-37"
  "abierto" => array:3 [
    "ES" => false
    "ES2" => false
    "LATM" => false
  ]
  "gratuito" => false
  "lecturas" => array:2 [
    "total" => 4
    "formatos" => array:2 [
      "HTML" => 2
      "PDF" => 2
    ]
  ]
  "Traduccion" => array:1 [
    "es" => array:18 [
      "pii" => "S0014256517301807"
      "issn" => "00142565"
      "doi" => "10.1016/j.rce.2017.07.006"
      "estado" => "S300"
      "fechaPublicacion" => "2018-01-01"
      "aid" => "1421"
      "documento" => "article"
      "crossmark" => 1
      "subdocumento" => "ssu"
      "cita" => "Rev Clin Esp. 2018;218:29-37"
      "abierto" => array:3 [
        "ES" => false
        "ES2" => false
        "LATM" => false
      ]
      "gratuito" => false
      "lecturas" => array:2 [
        "total" => 197
        "formatos" => array:2 [
          "HTML" => 143
          "PDF" => 54
        ]
      ]
      "es" => array:13 [
        "idiomaDefecto" => true
        "cabecera" => "<span class="elsevierStyleTextfn">Revisi&#243;n</span>"
        "titulo" => "Tratamiento del virus de la hepatitis<span class="elsevierStyleHsp" style=""></span>C con antivirales de acci&#243;n directa&#58; Aspectos pr&#225;cticos y situaci&#243;n actual"
        "tienePdf" => "es"
        "tieneTextoCompleto" => "es"
        "tieneResumen" => array:2 [
          0 => "es"
          1 => "en"
        ]
        "paginas" => array:1 [
          0 => array:2 [
            "paginaInicial" => "29"
            "paginaFinal" => "37"
          ]
        ]
        "titulosAlternativos" => array:1 [
          "en" => array:1 [
            "titulo" => "Treatment of hepatitis<span class="elsevierStyleHsp" style=""></span>C virus with direct-acting antivirals&#58; Practical aspects and current situation"
          ]
        ]
        "contieneResumen" => array:2 [
          "es" => true
          "en" => true
        ]
        "contieneTextoCompleto" => array:1 [
          "es" => true
        ]
        "contienePdf" => array:1 [
          "es" => true
        ]
        "resumenGrafico" => array:2 [
          "original" => 0
          "multimedia" => array:7 [
            "identificador" => "fig0010"
            "etiqueta" => "Figura 2"
            "tipo" => "MULTIMEDIAFIGURA"
            "mostrarFloat" => true
            "mostrarDisplay" => false
            "figura" => array:1 [
              0 => array:4 [
                "imagen" => "gr2.jpeg"
                "Alto" => 2058
                "Ancho" => 2489
                "Tamanyo" => 269207
              ]
            ]
            "descripcion" => array:1 [
              "es" => "<p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">Factores a tener en cuenta para la elecci&#243;n del r&#233;gimen terap&#233;utico&#46;</p>"
            ]
          ]
        ]
        "autores" => array:1 [
          0 => array:2 [
            "autoresLista" => "M&#46;J&#46; Vivancos, A&#46; Moreno, C&#46; Quereda"
            "autores" => array:3 [
              0 => array:2 [
                "nombre" => "M&#46;J&#46;"
                "apellidos" => "Vivancos"
              ]
              1 => array:2 [
                "nombre" => "A&#46;"
                "apellidos" => "Moreno"
              ]
              2 => array:2 [
                "nombre" => "C&#46;"
                "apellidos" => "Quereda"
              ]
            ]
          ]
        ]
      ]
      "idiomaDefecto" => "es"
      "Traduccion" => array:1 [
        "en" => array:9 [
          "pii" => "S2254887417301285"
          "doi" => "10.1016/j.rceng.2017.07.005"
          "estado" => "S300"
          "subdocumento" => ""
          "abierto" => array:3 [
            "ES" => false
            "ES2" => false
            "LATM" => false
          ]
          "gratuito" => false
          "lecturas" => array:1 [
            "total" => 0
          ]
          "idiomaDefecto" => "en"
          "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2254887417301285?idApp=WRCEE"
        ]
      ]
      "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0014256517301807?idApp=WRCEE"
      "url" => "/00142565/0000021800000001/v1_201801070655/S0014256517301807/v1_201801070655/es/main.assets"
    ]
  ]
  "itemSiguiente" => array:19 [
    "pii" => "S2254887417301200"
    "issn" => "22548874"
    "doi" => "10.1016/j.rceng.2017.10.002"
    "estado" => "S300"
    "fechaPublicacion" => "2018-01-01"
    "aid" => "1428"
    "copyright" => "Elsevier Espa&#241;a&#44; S&#46;L&#46;U&#46; and Sociedad Espa&#241;ola de Medicina Interna &#40;SEMI&#41;"
    "documento" => "article"
    "crossmark" => 1
    "subdocumento" => "sco"
    "cita" => "Rev Clin Esp. 2018;218:38-9"
    "abierto" => array:3 [
      "ES" => false
      "ES2" => false
      "LATM" => false
    ]
    "gratuito" => false
    "lecturas" => array:2 [
      "total" => 2
      "PDF" => 2
    ]
    "en" => array:11 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Medicine in images</span>"
      "titulo" => "Open thoracostomy as treatment of chronic empyema with bronchopleural fistula"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "38"
          "paginaFinal" => "39"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "Toracostom&#237;a abierta como tratamiento de un empiema cr&#243;nico con f&#237;stula broncopleural"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:6 [
          "identificador" => "fig0005"
          "etiqueta" => "Figure 1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "gr1.jpeg"
              "Alto" => 2077
              "Ancho" => 2500
              "Tamanyo" => 546253
            ]
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "M&#46;N&#46; Sol&#237;s-Marqu&#237;nez, J&#46;F&#46; L&#243;pez-Caleya"
          "autores" => array:2 [
            0 => array:2 [
              "nombre" => "M&#46;N&#46;"
              "apellidos" => "Sol&#237;s-Marqu&#237;nez"
            ]
            1 => array:2 [
              "nombre" => "J&#46;F&#46;"
              "apellidos" => "L&#243;pez-Caleya"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "Traduccion" => array:1 [
      "es" => array:9 [
        "pii" => "S0014256517301984"
        "doi" => "10.1016/j.rce.2017.08.001"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => false
          "ES2" => false
          "LATM" => false
        ]
        "gratuito" => false
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "es"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0014256517301984?idApp=WRCEE"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2254887417301200?idApp=WRCEE"
    "url" => "/22548874/0000021800000001/v1_201801040959/S2254887417301200/v1_201801040959/en/main.assets"
  ]
  "itemAnterior" => array:19 [
    "pii" => "S225488741730098X"
    "issn" => "22548874"
    "doi" => "10.1016/j.rceng.2017.09.001"
    "estado" => "S300"
    "fechaPublicacion" => "2018-01-01"
    "aid" => "1415"
    "copyright" => "Elsevier Espa&#241;a&#44; S&#46;L&#46;U&#46; and Sociedad Espa&#241;ola de Medicina Interna &#40;SEMI&#41;"
    "documento" => "article"
    "crossmark" => 1
    "subdocumento" => "ssu"
    "cita" => "Rev Clin Esp. 2018;218:22-8"
    "abierto" => array:3 [
      "ES" => false
      "ES2" => false
      "LATM" => false
    ]
    "gratuito" => false
    "lecturas" => array:2 [
      "total" => 2
      "PDF" => 2
    ]
    "en" => array:13 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Review</span>"
      "titulo" => "The pathophysiology of Fabry disease"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "tieneResumen" => array:2 [
        0 => "en"
        1 => "es"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "22"
          "paginaFinal" => "28"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "Fisiopatolog&#237;a de la enfermedad de Fabry"
        ]
      ]
      "contieneResumen" => array:2 [
        "en" => true
        "es" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:7 [
          "identificador" => "fig0005"
          "etiqueta" => "Figure 1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "gr1.jpeg"
              "Alto" => 1407
              "Ancho" => 3192
              "Tamanyo" => 200672
            ]
          ]
          "descripcion" => array:1 [
            "en" => "<p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Degradation pathway for complex lipids&#46;</p>"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "S&#46; Olivera-Gonz&#225;lez, C&#46; Josa-Laorden, M&#46;A&#46; Torralba-Cabeza"
          "autores" => array:3 [
            0 => array:2 [
              "nombre" => "S&#46;"
              "apellidos" => "Olivera-Gonz&#225;lez"
            ]
            1 => array:2 [
              "nombre" => "C&#46;"
              "apellidos" => "Josa-Laorden"
            ]
            2 => array:2 [
              "nombre" => "M&#46;A&#46;"
              "apellidos" => "Torralba-Cabeza"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "Traduccion" => array:1 [
      "es" => array:9 [
        "pii" => "S0014256517301571"
        "doi" => "10.1016/j.rce.2017.06.007"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => false
          "ES2" => false
          "LATM" => false
        ]
        "gratuito" => false
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "es"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0014256517301571?idApp=WRCEE"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S225488741730098X?idApp=WRCEE"
    "url" => "/22548874/0000021800000001/v1_201801040959/S225488741730098X/v1_201801040959/en/main.assets"
  ]
  "en" => array:20 [
    "idiomaDefecto" => true
    "cabecera" => "<span class="elsevierStyleTextfn">Review</span>"
    "titulo" => "Treatment of hepatitis C virus with direct-acting antivirals&#58; Practical aspects and current situation"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "29"
        "paginaFinal" => "37"
      ]
    ]
    "autores" => array:1 [
      0 => array:4 [
        "autoresLista" => "M&#46;J&#46; Vivancos, A&#46; Moreno, C&#46; Quereda"
        "autores" => array:3 [
          0 => array:2 [
            "nombre" => "M&#46;J&#46;"
            "apellidos" => "Vivancos"
          ]
          1 => array:2 [
            "nombre" => "A&#46;"
            "apellidos" => "Moreno"
          ]
          2 => array:4 [
            "nombre" => "C&#46;"
            "apellidos" => "Quereda"
            "email" => array:1 [
              0 => "carmen&#46;quereda&#64;salud&#46;madrid&#46;org"
            ]
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">&#42;</span>"
                "identificador" => "cor0005"
              ]
            ]
          ]
        ]
        "afiliaciones" => array:1 [
          0 => array:2 [
            "entidad" => "Servicio de Enfermedades Infecciosas&#44; Hospital Ram&#243;n y Cajal&#44; Madrid&#44; Spain"
            "identificador" => "aff0005"
          ]
        ]
        "correspondencia" => array:1 [
          0 => array:3 [
            "identificador" => "cor0005"
            "etiqueta" => "&#8270;"
            "correspondencia" => "Corresponding author&#46;"
          ]
        ]
      ]
    ]
    "titulosAlternativos" => array:1 [
      "es" => array:1 [
        "titulo" => "Tratamiento del virus de la hepatitis C con antivirales de acci&#243;n directa&#58; Aspectos pr&#225;cticos y situaci&#243;n actual"
      ]
    ]
    "resumenGrafico" => array:2 [
      "original" => 0
      "multimedia" => array:7 [
        "identificador" => "fig0005"
        "etiqueta" => "Figure 1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr1.jpeg"
            "Alto" => 1528
            "Ancho" => 2353
            "Tamanyo" => 232489
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Replication cycle of hepatitis C virus and therapeutic targets&#46;</p>"
        ]
      ]
    ]
    "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0025">Background</span><p id="par0005" class="elsevierStylePara elsevierViewall">The hepatitis C virus &#40;HCV&#41; affects more than 170 million individuals worldwide&#46;<a class="elsevierStyleCrossRefs" href="#bib0185"><span class="elsevierStyleSup">1&#44;2</span></a> HCV is the main cause of hepatic cirrhosis and hepatocarcinoma and is the most common indication for liver transplantation&#46;<a class="elsevierStyleCrossRefs" href="#bib0195"><span class="elsevierStyleSup">3&#44;4</span></a> Half a million individuals die every year from HCV-related liver disease&#46;<a class="elsevierStyleCrossRef" href="#bib0205"><span class="elsevierStyleSup">5</span></a></p><p id="par0010" class="elsevierStylePara elsevierViewall">The HCV genome does not integrate with that of the host&#44; and therefore its replication can be definitively inhibited&#44; curing the infection&#46; It has been shown that the sustained viral response &#40;SVR&#41; achieved with HCV treatment improves the histology and progression of liver disease&#46;<a class="elsevierStyleCrossRefs" href="#bib0210"><span class="elsevierStyleSup">6&#44;7</span></a> Chronic liver disease due to HCV began to be treated in 1991 with subcutaneous interferon alpha in monotherapy&#46; The efficacy of this treatment regimen was low&#44; and tolerance was poor&#46; In 1998&#44; ribavirin was included in the treatment&#44; improving the SVR rates but without significantly increasing the adverse effects of interferon&#46; In 2000&#44; conventional interferon alpha was replaced by pegylated interferon &#40;alpha 2a or alpha 2b&#41;&#44; improving the response and tolerance&#46; Neither interferon nor ribavirin have a direct antiviral effect against HCV but instead act by an immune-mediated mechanism&#46;</p><p id="par0015" class="elsevierStylePara elsevierViewall">Telaprevir and boceprevir&#44; the first direct-acting antivirals &#40;DAAs&#41; employed for treating chronic HCV infection&#44; were marketed in 2011&#46; Their mechanism of action inhibits the HCV protease &#40;PI&#41;&#46; These DAAs were approved for treatment in combination with pegylated interferon and ribavirin&#46;<a class="elsevierStyleCrossRef" href="#bib0220"><span class="elsevierStyleSup">8</span></a> Although this treatment regimen achieved a significant increase in the percentage of patients with SVR&#44; the regimen had significant limitations&#58; it was only effective for patients with genotype 1&#44; the treatment regimens were complex&#44; the number of pills were high&#44; the patients had intolerance or were contraindicated for interferon&#44; and the efficacy in subgroups with predictors of poor response continued to be low&#46;</p><p id="par0020" class="elsevierStylePara elsevierViewall">In 2013&#44; new DAAs began to appear&#44; which inhibited some of the steps in the virus replication cycle&#46; Using combinations of these drugs&#44; highly effective&#44; short and well-tolerated interferon-free treatment regimens have been achieved&#44; which have revolutionized HCV treatment&#44; even for patients with advanced stages of cirrhosis&#46;<a class="elsevierStyleCrossRefs" href="#bib0225"><span class="elsevierStyleSup">9&#8211;11</span></a></p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0030">Replication cycle of the hepatitis C virus&#46; Therapeutic targets</span><p id="par0025" class="elsevierStylePara elsevierViewall">HCV is an RNA virus of the <span class="elsevierStyleItalic">Flaviviridae</span> family&#46; To date&#44; 6 genotypes have been described &#40;1a&#47;1b&#44; 2&#44; 3&#44; 4&#44; 5 and 6&#41;&#46; In Europe and the United States&#44; the most common genotype is 1&#44; followed by genotypes 3 and 4&#46;<a class="elsevierStyleCrossRefs" href="#bib0185"><span class="elsevierStyleSup">1&#44;2</span></a> As with the human immunodeficiency virus &#40;HIV&#41;&#44; HCV has a high viral replication rate and a low error correction capability due to its polymerase RNA&#46; For patients with chronic infection&#44; these characteristics promote a considerable diversity of viral quasispecies&#46; However&#44; HCV does not integrate with the infected host&#39;s genome&#44; and HCV&#39;s entire cycle is performed in the cytoplasm&#46; Treatments that effectively block its replication can therefore eradicate the infection&#46; The replication cycle of HCV offers numerous therapeutic targets &#40;<a class="elsevierStyleCrossRef" href="#fig0005">Fig&#46; 1</a>&#41;&#46;</p><elsevierMultimedia ident="fig0005"></elsevierMultimedia><p id="par0030" class="elsevierStylePara elsevierViewall">The HCV virion enters the cells by endocytosis through a receptor&#46; HCV then releases its genome&#44; which is directed to the cell&#39;s endoplasmic reticulum&#44; where it forms a polyprotein of approximately 3011 amino acids through a translation process&#46; The HCV protease&#44; encoded by the NS3&#47;4A genome region&#44; is responsible &#40;along with other cell proteases&#41; for completing the hydrolysis of this polyprotein&#44; which is segmented into 3 structural and 7 nonstructural proteins&#46;<a class="elsevierStyleCrossRef" href="#bib0240"><span class="elsevierStyleSup">12</span></a> Inhibitors of this viral protease have been designed that bind to the viral&#39;s active center&#44; blocking its action and viral replication&#46; The composed proteins and the viral RNA interact with the NS5A protein&#44; which is associated with the membrane and is phosphorylated by a cell serine-kinase&#46; The NS5A protein has no known enzymatic function but is essential for RNA replication and the assembly of new viral particles&#46;<a class="elsevierStyleCrossRef" href="#bib0240"><span class="elsevierStyleSup">12</span></a> NS5A inhibitors block the binding with proteins and inhibit the relationship between the NS5A protein and the locations of HCV intracellular replication&#46;</p><p id="par0035" class="elsevierStylePara elsevierViewall">Moreover&#44; a nonstructural RNA-dependent RNA polymerase protein &#40;NS5B&#41; is also involved in viral RNA replication&#44; which produces a negative-strand RNA and serves as a mold for manufacturing positive-strand RNA&#46; The NS5B nucleoside analogues incorporate in the RNA and block the chain&#44; inhibiting HCV replication through the binding to the enzyme&#39;s catalytic site &#40;conserved&#41;&#46; This area is common in all genotypes&#59; the drugs that act on this target are therefore active against all genotypes &#40;pangenotypics&#41;&#46; In contrast&#44; non-nucleoside NS5B inhibitors are noncompetitive inhibitors&#44; which block RNA synthesis before the start of the chain and are more dependent on the viral genotype&#46;<a class="elsevierStyleCrossRef" href="#bib0240"><span class="elsevierStyleSup">12</span></a> The newly manufactured viral genomes can once again be replicated and translated or packaged to form new viral particles&#46; These new viral particles are released by exocytosis&#44; completing the cycle&#46;<a class="elsevierStyleCrossRef" href="#bib0245"><span class="elsevierStyleSup">13</span></a></p></span><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0035">Direct-acting antivirals&#46; Classification according to their mechanism of action</span><p id="par0040" class="elsevierStylePara elsevierViewall">The currently available DAAs are classified according to the target of the HCV replication cycle on which they act&#58;<ul class="elsevierStyleList" id="lis0005"><li class="elsevierStyleListItem" id="lsti0005"><span class="elsevierStyleLabel">-</span><p id="par0045" class="elsevierStylePara elsevierViewall">Protease inhibitors &#40;PI&#41; NS3&#47;4A&#46;</p></li><li class="elsevierStyleListItem" id="lsti0010"><span class="elsevierStyleLabel">-</span><p id="par0050" class="elsevierStylePara elsevierViewall">NS5A protein inhibitors&#46;</p></li><li class="elsevierStyleListItem" id="lsti0015"><span class="elsevierStyleLabel">-</span><p id="par0055" class="elsevierStylePara elsevierViewall">NS5B polymerase inhibitors&#44; which in turn can be nucleoside analogues and non-nucleoside analogues&#46;</p></li></ul></p><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0040">NS3&#47;4A protease inhibitors</span><p id="par0060" class="elsevierStylePara elsevierViewall">These agents act by inhibiting the HCV protease NS3&#47;4A and thereby the replication of the virus&#46; The drugs belonging to this family are named with the suffix &#8220;previr&#8221;&#46; Telaprevir and boceprevir were the first to be used and are therefore considered first-generation HCV PIs&#46;<a class="elsevierStyleCrossRefs" href="#bib0250"><span class="elsevierStyleSup">14&#44;15</span></a> Due to their above-mentioned limitations&#44; the drugs were replaced by other PIs&#46;</p><p id="par0065" class="elsevierStylePara elsevierViewall">The second and third-generation PIs&#44; which have been marketed&#44; are polygenotypic drugs with activity against the HCV genotypes 1&#44; 2 and 4 &#40;although the drugs are not used for HCV genotype 2&#41;&#46; However&#44; the drugs have no activity against genotype 3&#44; and there is little experience with genotypes 5 to 7&#46; Within genotype 1&#44; the drugs are more active against subtype 1b&#46; The first-generation PIs have greater potency&#44; safety&#44; tolerance and a longer half-life&#44; which allow them to be administered once a day with fewer drug interactions&#46; Nevertheless&#44; potential interactions should be checked&#44; and the patient should be instructed not to take any new drug without a previous consultation&#46;<a class="elsevierStyleCrossRef" href="#bib0260"><span class="elsevierStyleSup">16</span></a> Although resistant mutations can be generated in patients treated with these drugs&#44; the genetic barrier of these drugs to resistance is much greater than that of first-generation PIs&#46; The resistance mutations generated during treatment with some of these drugs does not jeopardize the response with other drugs of the same family&#46;</p><p id="par0070" class="elsevierStylePara elsevierViewall">The currently approved HCV PIs in Europe and the US are simeprevir&#44; paritaprevir &#40;which are administered boosted with ritonavir&#41; and grazoprevir&#46; Glecaprevir &#40;AbbVie&#41;<a class="elsevierStyleCrossRef" href="#bib0265"><span class="elsevierStyleSup">17</span></a> and voxilaprevir &#40;Gilead&#41;<a class="elsevierStyleCrossRef" href="#bib0270"><span class="elsevierStyleSup">18</span></a> are 2 potent new-generation pangenotypic PIs&#44; with activity against genotype 3 and are currently in advanced phases of research&#46;</p></span><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0045">NS5A inhibitors</span><p id="par0075" class="elsevierStylePara elsevierViewall">These drugs act by inhibiting the NS5A replication complex&#46; The drugs that belong to this family are pangenotypic and are named with the suffix &#8220;asvir&#8221;&#46; As with the PIs&#44; the drugs have greater activity within genotype 1 against subtype 1b&#46; The drugs are potent&#44; well-tolerated and have pharmacokinetics that allows for administration once a day&#46; Their adverse effects are generally mild&#46; Although these drugs generally have fewer interactions than PIs&#44; the interactions should always be considered when these drugs are used concomitantly with other drugs&#46;<a class="elsevierStyleCrossRef" href="#bib0260"><span class="elsevierStyleSup">16</span></a></p><p id="par0080" class="elsevierStylePara elsevierViewall">The currently approved NS5A inhibitors in Europe and the US are daclatasvir&#44; ombitasvir&#44; ledipasvir&#44; velpatasvir and elbasvir&#46; All but the first are coformulated with another DAA&#46; Pibrentasvir is a new NS5A inhibitor&#44; which will be used coformulated with glecaprevir &#40;AbbVie&#41;&#46;<a class="elsevierStyleCrossRef" href="#bib0265"><span class="elsevierStyleSup">17</span></a> The drug is still being researched&#44; but the results from phase III studies have been presented&#44; with excellent results in all genotypes&#44; without needing to add ribavirin&#46;<a class="elsevierStyleCrossRef" href="#bib0265"><span class="elsevierStyleSup">17</span></a></p><p id="par0085" class="elsevierStylePara elsevierViewall">The genetic barrier of this family of drugs is moderate&#46; Resistance mutations are frequently selected in patients who fail a treatment regimen that includes one of these drugs&#46; This possibility is lower with more modern NS5A inhibitors &#40;velpatasvir&#44; elbasvir and pibrentasvir&#41;&#46;<a class="elsevierStyleCrossRef" href="#bib0275"><span class="elsevierStyleSup">19</span></a></p></span><span id="sec0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0050">NS5B polymerase inhibitors</span><p id="par0090" class="elsevierStylePara elsevierViewall">These drugs act by inhibiting the HCV RNA polymerase NS5B&#46; Drugs belonging to this family are named with the suffix &#8220;buvir&#8221;&#46; There are 2 types of these drugs&#58; nucleoside analogues and non-nucleoside analogues&#46; We currently only have sofosbuvir in the first group and dasabuvir in the second&#46;</p><p id="par0095" class="elsevierStylePara elsevierViewall">The general characteristics of NS5B nucleoside analogue polymerase inhibitors are as follows&#58; &#40;1&#41; high antiviral potency&#59; &#40;2&#41; high barrier to resistance&#59; &#40;3&#41; pangenotypics&#59; &#40;4&#41; easy posology&#44; and &#40;5&#41; few adverse effects and interactions&#46; These characteristics make the drugs attractive as components of any treatment regimen&#46; In contrast&#44; NS5B non-nucleoside analogue polymerase inhibitors&#44; although safe and well-tolerated&#44; have low antiviral potency&#44; limited activity against genotype 1 and a low genetic barrier&#44; which frequently results in the appearance of strains with resistance mutations in the therapeutic failures&#46;</p></span></span><span id="sec0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0055">Characteristics of the available drugs for HCV treatment</span><span id="sec0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0060">Drugs without coformulation</span><span id="sec0045" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0065">Simeprevir &#40;Olysio<span class="elsevierStyleSup">&#174;</span>&#44; Janssen&#41;</span><p id="par0100" class="elsevierStylePara elsevierViewall">This is a second-generation HCV PI that is effective in patients with genotypes 1 and 4&#46; Dosages of 150<span class="elsevierStyleHsp" style=""></span>mg a day are employed&#44; in 12 to 24-week regimens&#46; There is experience with the use of simeprevir combined with pegylated interferon and ribavirin&#44;<a class="elsevierStyleCrossRef" href="#bib0280"><span class="elsevierStyleSup">20</span></a> with sofosbuvir<a class="elsevierStyleCrossRef" href="#bib0285"><span class="elsevierStyleSup">21</span></a> and with daclatasvir&#46;<a class="elsevierStyleCrossRef" href="#bib0290"><span class="elsevierStyleSup">22</span></a> When combined with sofosbuvir&#44; simeprevir has shown SVR rates of more than 80&#37;&#59; the combination with ribavirin does not improve the results&#46;<a class="elsevierStyleCrossRef" href="#bib0295"><span class="elsevierStyleSup">23</span></a> When combined with daclatasvir&#44; the results are unsatisfactory&#44; and there is very little experience with this combination&#46; The response rates with simeprevir are lower in patients with genotype 1 and the Q80K mutation&#44; especially in regimens in which it is combined with interferon and ribavirin&#46;<a class="elsevierStyleCrossRef" href="#bib0280"><span class="elsevierStyleSup">20</span></a> The drug is not recommended for patients who have previously failed regimens with an HCV PI&#46;<a class="elsevierStyleCrossRef" href="#bib0300"><span class="elsevierStyleSup">24</span></a></p><p id="par0105" class="elsevierStylePara elsevierViewall">Simeprevir is a very well-tolerated drug&#44; with generally mild adverse effects&#46; The most common adverse effects include skin rashes&#44; photosensitivity and increased transaminase and bilirubin levels&#46;<a class="elsevierStyleCrossRef" href="#bib0305"><span class="elsevierStyleSup">25</span></a> The drug is not recommended for patients with advanced liver disease &#40;Child&#8211;Pugh classes B and C&#41;&#44; because the disease can increase its serum levels and its toxicity&#46; Interactions can occur with other cytochrome P450 3A inducers and inhibitors&#46;</p><p id="par0110" class="elsevierStylePara elsevierViewall">Due to its lower potency&#44; potential drug interactions and lack of coformulation with other agents against HCV&#44; simeprevir is rarely used and has been displaced by other options&#46; The drug can still have a certain usefulness for the few patients for whom other regimens with DAA fail&#46;<a class="elsevierStyleCrossRef" href="#bib0300"><span class="elsevierStyleSup">24</span></a></p></span><span id="sec0050" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0070">Daclatasvir &#40;Daklinza<span class="elsevierStyleSup">&#174;</span>&#44; BMS&#41;</span><p id="par0115" class="elsevierStylePara elsevierViewall">This drug is a first-generation NS5A protein inhibitor&#44; active against genotypes 1 to 6&#46; Dosages of 60<span class="elsevierStyleHsp" style=""></span>mg a day are employed&#44; in 12 to 24-week regimens&#46; The dose must be reduced to 30<span class="elsevierStyleHsp" style=""></span>mg when used with atazanavir-ritonavir&#44; azole or clarithromycin&#46; If used along with efavirenz&#44; etravirine or dexamethasone&#44; the dosage should be increased to 90<span class="elsevierStyleHsp" style=""></span>mg a day&#46;<a class="elsevierStyleCrossRef" href="#bib0310"><span class="elsevierStyleSup">26</span></a> Although there is experience with the drug combined with various DAAs&#44; the most studied and effective regimen is the combination with sofosbuvir&#44; with or without ribavirin&#46; Despite its safety and efficacy&#44; the regimen is not a first-choice regimen&#44; because there are other more comfortable options with better cost-efficiency&#46;</p></span><span id="sec0055" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0075">Sofosbuvir &#40;Sovaldi<span class="elsevierStyleSup">&#174;</span>&#44; Gilead&#41;</span><p id="par0120" class="elsevierStylePara elsevierViewall">This is an NS5B polymerase inhibitor of the HCV nucleoside analogue and has shown its potent antiviral pangenotypic activity&#46; The drug is effective when combined with other DAAs and when combined with ribavirin in genotype 2&#46; Unlike PIs and NS5A inhibitors and within genotype 1&#44; the drug is more effective against 1a&#46; Its dosage is 400<span class="elsevierStyleHsp" style=""></span>mg once a day&#44; in 8 to 24-week regimens&#46;<a class="elsevierStyleCrossRef" href="#bib0315"><span class="elsevierStyleSup">27</span></a> Sofosbuvir is a safe drug&#44; with few interaction problems&#44; but is not recommended for patients with an estimated glomerular filtration rate &#60;30<span class="elsevierStyleHsp" style=""></span>mL&#47;min&#47;1&#46;73<span class="elsevierStyleHsp" style=""></span>m<span class="elsevierStyleSup">2</span>&#46; One of the drug&#39;s most distinctive features is its high genetic barrier&#44; with no reports of selection of resistant mutations after failures&#46;<a class="elsevierStyleCrossRef" href="#bib0315"><span class="elsevierStyleSup">27</span></a> This feature makes the drug essential for rescue treatments&#46;</p></span><span id="sec0060" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0080">Ribavirin</span><p id="par0125" class="elsevierStylePara elsevierViewall">Although not a DAA&#44; ribavirin is still used for treating HCV&#44; when combined with other drugs&#46;<a class="elsevierStyleCrossRef" href="#bib0235"><span class="elsevierStyleSup">11</span></a> The drug is used at dosages of 800 to 1200<span class="elsevierStyleHsp" style=""></span>mg a day&#44; adjusted for weight and renal function&#44; in 2 separate doses&#46; Its current use is limited as a supplementary drug in DAA combinations that have shown increased efficacy&#46; Ribavirin&#39;s main adverse effect is hemolytic anemia&#46;</p></span></span><span id="sec0065" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0085">Coformulated drugs</span><span id="sec0070" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0090">Paritaprevir&#47;ritonavir&#47;ombitasvir &#40;Viekirax<span class="elsevierStyleSup">&#174;</span>&#44; Abbvie&#41; with or without dasabuvir &#40;Exviera<span class="elsevierStyleSup">&#174;</span>&#44; Abbvie&#41;</span><p id="par0130" class="elsevierStylePara elsevierViewall">These drugs are known as the Abbvie 2D and 3D combos&#46; The first drug combines a ritonavir-boosted HCV PI &#40;paritaprevir&#41; and an NS5A inhibitor &#40;ombitasvir&#41; in a single pill&#46; The dosage is 2 tablets once a day&#46; The drug is indicated for the treatment of patients with genotypes 1 and 4&#46; For patients with genotype 1&#44; the drug is combined with dasabuvir&#59; if the genotype is 1a&#44; ribavirin is also added&#46; Dasabuvir is not used for patients with genotype 4 but is combined with ribavirin&#46;<a class="elsevierStyleCrossRef" href="#bib0320"><span class="elsevierStyleSup">28</span></a></p><p id="par0135" class="elsevierStylePara elsevierViewall">Reviewing all potential interactions is recommended before starting treatment&#46; If the patient is HIV positive&#44; it is important that the HIV viral load be undetectable with its antiretroviral therapy before starting this regimen that includes ritonavir&#44; to prevent the development of resistances&#46;<a class="elsevierStyleCrossRef" href="#bib0320"><span class="elsevierStyleSup">28</span></a> An adjustment is not necessary in the event of renal failure&#46; The drug should not be used in patients with advanced liver disease &#40;Child&#8211;Pugh classes B and C&#41;<a class="elsevierStyleCrossRef" href="#bib0320"><span class="elsevierStyleSup">28</span></a> or in patients who have previously failed regimens with other PIs&#46;<a class="elsevierStyleCrossRef" href="#bib0320"><span class="elsevierStyleSup">28</span></a></p><p id="par0140" class="elsevierStylePara elsevierViewall">Dasabuvir is a non-nucleoside analogue polymerase inhibitor of HCV and is only active against genotype 1&#46; The drug has less potency than other DAAs and is therefore always used in combination with paritaprevir&#47;ritonavir and ombitasvir&#46; Dasabuvir is well tolerated and safe and is administered every 12<span class="elsevierStyleHsp" style=""></span>h&#46;</p><p id="par0145" class="elsevierStylePara elsevierViewall">The combination of paritaprevir&#47;ritonavir&#44; ombitasvir and dasabuvir for treating HCV is considered a safe and well-tolerated regimen&#44; with a high success rate &#40;greater than 90&#37;&#41; and a lower cost than other therapeutic options&#46; The combination has also been shown safe in renal failure and does not require dose adjustment&#46; However&#44; its disadvantages are the larger number of pills than other therapeutic options&#44; the need for twice daily administration and the larger number of drug interactions&#46;<a class="elsevierStyleCrossRef" href="#bib0260"><span class="elsevierStyleSup">16</span></a></p></span><span id="sec0075" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0095">Grazoprevir&#47;elbasvir &#40;Zepatier<span class="elsevierStyleSup">&#174;</span>&#44; MSD&#41;</span><p id="par0150" class="elsevierStylePara elsevierViewall">This recently approved formulation combines 100<span class="elsevierStyleHsp" style=""></span>mg of grazoprevir &#40;HCV PI&#41; and 50<span class="elsevierStyleHsp" style=""></span>mg of elbasvir &#40;NS5A inhibitor&#41; in a single tablet&#44; administered once a day&#46;<a class="elsevierStyleCrossRef" href="#bib0325"><span class="elsevierStyleSup">29</span></a> The combination is approved for genotypes 1&#44; 4 and 6 and has shown its efficacy in patients coinfected with HIV and in advanced kidney disease stages IV and V&#44; including patients undergoing dialysis&#46; Its efficacy is above 90&#37;&#46; However&#44; the response rates are lower in genotype 1 when there are baseline NS5A resistance-associated polymorphisms at positions 28&#44; 30&#44; 31 or 93&#46;<a class="elsevierStyleCrossRef" href="#bib0325"><span class="elsevierStyleSup">29</span></a> In these cases or when a baseline resistance test is unavailable&#44; it is advisable to add ribavirin and extend the treatment to 16 weeks&#46;<a class="elsevierStyleCrossRef" href="#bib0325"><span class="elsevierStyleSup">29</span></a> If a patient has previously been treated with an HCV PI&#44; it is advisable to add ribavirin&#46;</p></span><span id="sec0080" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0100">Sofosbuvir&#47;ledipasvir &#40;Harvoni<span class="elsevierStyleSup">&#174;</span>&#44; Gilead&#41;</span><p id="par0155" class="elsevierStylePara elsevierViewall">This combination includes 400<span class="elsevierStyleHsp" style=""></span>mg of sofosbuvir and 90<span class="elsevierStyleHsp" style=""></span>mg of ledipasvir &#40;an NS5A inhibitor&#41; in a single tablet&#46; This was the first drug combination marketed for the treatment of HCV&#46; There is extensive experience with patients with genotypes 1 and 4&#44; in any stage of fibrosis&#44; including decompensated cirrhosis&#46;<a class="elsevierStyleCrossRef" href="#bib0330"><span class="elsevierStyleSup">30</span></a> The success rate of this combination in genotypes 1 and 4 is above 90&#37;&#46; The combination is less effective for genotype 3&#44; with which there is less experience&#46;</p><p id="par0160" class="elsevierStylePara elsevierViewall">For patients with genotype 1a for whom other regimens have failed&#44; it has been shown that the presence of mutations that confer high resistance to ledipasvir significantly decreases the treatment efficacy&#46; Therefore&#44; if these mutations are present or cannot be ruled out&#44; adding ribavirin to treatment regimen is recommended&#46;</p><p id="par0165" class="elsevierStylePara elsevierViewall">This combination has few drug interactions&#46;<a class="elsevierStyleCrossRef" href="#bib0260"><span class="elsevierStyleSup">16</span></a> Ledipasvir requires a low gastric pH for its absorption&#44; and proton pump inhibitors can decrease its efficacy&#46; When administered with tenofovir and an HIV PI&#44; the patient&#39;s renal function should be monitored&#46;<a class="elsevierStyleCrossRef" href="#bib0335"><span class="elsevierStyleSup">31</span></a> As with the use of sofosbuvir in isolation&#44; there is barely any experience when the glomerular filtration rate is lower than 30<span class="elsevierStyleHsp" style=""></span>mL&#47;min&#47;1&#46;73<span class="elsevierStyleHsp" style=""></span>m<span class="elsevierStyleSup">2</span>&#46;</p></span><span id="sec0085" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0105">Sofosbuvir&#47;velpatasvir &#40;Epclusa<span class="elsevierStyleSup">&#174;</span>&#44; Gilead&#41;</span><p id="par0170" class="elsevierStylePara elsevierViewall">This new combination of sofosbuvir and a second-generation NS5A inhibitor improves the activity against genotypes 2 and 3&#44; compared with ledipasvir&#46;<a class="elsevierStyleCrossRef" href="#bib0340"><span class="elsevierStyleSup">32</span></a> This combination is pangenotypic and is approved for genotypes 1 to 6&#46; The treatment duration is generally 12 weeks&#44; except for decompensated cirrhosis with genotype 3&#46; It is advisable to combine ribavirin only for decompensated cirrhosis and for pretreated patients or those with cirrhosis with the Y93H mutation and genotype 3 &#40;because the presence of this mutation in these patients is associated with reduced response&#41;&#46; The combinations main adverse effects are headache&#44; fatigue&#44; irritability and nausea&#46; The effects are usually mild and do not usually require withdrawal of the drug&#46;</p></span></span></span><span id="sec0090" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0110">Indications for treatment</span><p id="par0175" class="elsevierStylePara elsevierViewall">It is recommended that all patients with active HCV infection start treatment&#44;<a class="elsevierStyleCrossRef" href="#bib0230"><span class="elsevierStyleSup">10</span></a> whose objective is to reduce morbidity and mortality&#46; In decompensated cirrhosis&#44; the possibility of DAA treatment has changed these patients&#8217; natural history&#44; although the indication for transplantation cannot always be avoided&#46;<a class="elsevierStyleCrossRef" href="#bib0345"><span class="elsevierStyleSup">33</span></a></p><p id="par0180" class="elsevierStylePara elsevierViewall">Treatment in less advanced stages of fibrosis has been associated with a higher success rate&#44; a possibility of healing with shorter treatments and fewer adverse effects&#46; The effect of treatment on reducing transmission and eradicating the HCV infection is increasingly significant&#46;<a class="elsevierStyleCrossRef" href="#bib0350"><span class="elsevierStyleSup">34</span></a></p></span><span id="sec0095" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0115">Practical aspects of the treatment of chronic liver disease due to HCV</span><p id="par0185" class="elsevierStylePara elsevierViewall">Before starting HCV treatment&#44; we need the results of general laboratory tests&#44; the HCV genotype and subtype&#44; the viral load and the degree of hepatic fibrosis &#40;<a class="elsevierStyleCrossRef" href="#fig0010">Fig&#46; 2</a>&#41;&#46; We need to know the history of previous antiviral treatment failures and assess the presence of comorbidities&#46; It is important to determine the concomitant medication and review the potential interactions with the DAAs&#46; A simple&#44; fast and reliable way to do this is to use the University of Liverpool website &#40;hep-druginteractions&#46;org&#41;&#46;<a class="elsevierStyleCrossRef" href="#bib0260"><span class="elsevierStyleSup">16</span></a> It is also essential that patients be aware of the importance of good treatment adherence&#46;</p><elsevierMultimedia ident="fig0010"></elsevierMultimedia><p id="par0190" class="elsevierStylePara elsevierViewall">Except in highly specific circumstances that have already been mentioned&#44; the baseline resistances of the virus prior to the start of treatment have no impact on the SVR&#46;<a class="elsevierStyleCrossRef" href="#bib0355"><span class="elsevierStyleSup">35</span></a> Performing a baseline resistances study to guide the treatment regimen is therefore not recommended&#46;</p><p id="par0195" class="elsevierStylePara elsevierViewall">For patients with advanced fibrosis &#40;F3-F4&#41;&#44; an abdominal ultrasound should be available to rule out hepatocarcinoma&#46; Patients with cirrhosis and transient elastography readings higher than 20<span class="elsevierStyleHsp" style=""></span>kPa should also undergo upper endoscopy for the screening of esophageal varices&#46;<a class="elsevierStyleCrossRef" href="#bib0360"><span class="elsevierStyleSup">36</span></a> As with patients with advanced fibrosis and cirrhosis&#44; the SVR does not fully discount the possibility of developing an hepatocarcinoma&#46; Abdominal ultrasonography should be continued&#44; performing it every 6 months&#44; regardless of whether the HCV is cured&#46; During follow-up&#44; the only essential viral load is that measured 12 weeks after ending the treatment&#59; this reading will determine the SVR&#46;<a class="elsevierStyleCrossRef" href="#bib0235"><span class="elsevierStyleSup">11</span></a></p></span><span id="sec0100" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0120">Treatment regimens</span><p id="par0200" class="elsevierStylePara elsevierViewall">HCV treatment currently consists of the combination of at least 2 DAAs with different targets against the virus&#46;<a class="elsevierStyleCrossRef" href="#bib0235"><span class="elsevierStyleSup">11</span></a> Ribavirin is added in those situations in which it has been shown to increase the possibility of achieving an SVR&#46; Treatment duration varies from 8 to 24 weeks&#59; longer regimens are indicated for patients with decompensated cirrhosis&#46; The main characteristics of the employed combinations are summarized in <a class="elsevierStyleCrossRef" href="#fig0015">Fig&#46; 3</a>&#46; The treatment guidelines from the following associations should be reviewed in all cases&#58; the Spanish Association for the Study of the Liver&#44; the Spanish Society of Infectious Diseases and Clinical Microbiology&#44;<a class="elsevierStyleCrossRef" href="#bib0235"><span class="elsevierStyleSup">11</span></a> the European Association for the Study of the Liver<a class="elsevierStyleCrossRef" href="#bib0230"><span class="elsevierStyleSup">10</span></a> and the American Association for the Study of Liver Diseases&#46;<a class="elsevierStyleCrossRef" href="#bib0225"><span class="elsevierStyleSup">9</span></a></p><elsevierMultimedia ident="fig0015"></elsevierMultimedia><p id="par0205" class="elsevierStylePara elsevierViewall">The financial cost should also be considered when selecting the treatment regimen&#46; In Spain&#44; the price of the various drugs varies among the autonomous communities&#46; It is therefore important to consult the local guidelines that assess the cost-effectiveness of the drugs&#46;</p><p id="par0210" class="elsevierStylePara elsevierViewall">The recommended treatment regimens according to HCV genotype are listed in <a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>&#46; Combinations with simeprevir or daclatasvir are not included &#40;the latter except for genotypes 2 and 3&#41;&#44; because they offer no advantages over other more comfortable combinations with greater experience and lower cost&#46; In the European guidelines&#44; simeprevir appears as an alternative in genotype 4&#44; both in cirrhosis and in no cirrhosis&#46; Daclatasvir appears as an alternative for 12 or 24 weeks&#44; with or without ribavirin&#44; in all genotypes&#46;</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia></span><span id="sec0105" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0125">Conflict of interests</span><p id="par0215" class="elsevierStylePara elsevierViewall">C&#46; Quereda has participated in consulting activities for AbbVie&#44; Gilead and MSD laboratories&#44; as a speaker in AbbVie meetings and has occasionally attended congresses with funding from AbbVie&#44; Gilead and Jansen&#46;</p></span></span>"
    "textoCompletoSecciones" => array:1 [
      "secciones" => array:13 [
        0 => array:3 [
          "identificador" => "xres964031"
          "titulo" => "Abstract"
          "secciones" => array:1 [
            0 => array:1 [
              "identificador" => "abst0005"
            ]
          ]
        ]
        1 => array:2 [
          "identificador" => "xpalclavsec934100"
          "titulo" => "Keywords"
        ]
        2 => array:3 [
          "identificador" => "xres964032"
          "titulo" => "Resumen"
          "secciones" => array:1 [
            0 => array:1 [
              "identificador" => "abst0010"
            ]
          ]
        ]
        3 => array:2 [
          "identificador" => "xpalclavsec934101"
          "titulo" => "Palabras clave"
        ]
        4 => array:2 [
          "identificador" => "sec0005"
          "titulo" => "Background"
        ]
        5 => array:2 [
          "identificador" => "sec0010"
          "titulo" => "Replication cycle of the hepatitis C virus&#46; Therapeutic targets"
        ]
        6 => array:3 [
          "identificador" => "sec0015"
          "titulo" => "Direct-acting antivirals&#46; Classification according to their mechanism of action"
          "secciones" => array:3 [
            0 => array:2 [
              "identificador" => "sec0020"
              "titulo" => "NS3&#47;4A protease inhibitors"
            ]
            1 => array:2 [
              "identificador" => "sec0025"
              "titulo" => "NS5A inhibitors"
            ]
            2 => array:2 [
              "identificador" => "sec0030"
              "titulo" => "NS5B polymerase inhibitors"
            ]
          ]
        ]
        7 => array:3 [
          "identificador" => "sec0035"
          "titulo" => "Characteristics of the available drugs for HCV treatment"
          "secciones" => array:2 [
            0 => array:3 [
              "identificador" => "sec0040"
              "titulo" => "Drugs without coformulation"
              "secciones" => array:4 [
                0 => array:2 [
                  "identificador" => "sec0045"
                  "titulo" => "Simeprevir &#40;Olysio&#44; Janssen&#41;"
                ]
                1 => array:2 [
                  "identificador" => "sec0050"
                  "titulo" => "Daclatasvir &#40;Daklinza&#44; BMS&#41;"
                ]
                2 => array:2 [
                  "identificador" => "sec0055"
                  "titulo" => "Sofosbuvir &#40;Sovaldi&#44; Gilead&#41;"
                ]
                3 => array:2 [
                  "identificador" => "sec0060"
                  "titulo" => "Ribavirin"
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "sec0065"
              "titulo" => "Coformulated drugs"
              "secciones" => array:4 [
                0 => array:2 [
                  "identificador" => "sec0070"
                  "titulo" => "Paritaprevir&#47;ritonavir&#47;ombitasvir &#40;Viekirax&#44; Abbvie&#41; with or without dasabuvir &#40;Exviera&#44; Abbvie&#41;"
                ]
                1 => array:2 [
                  "identificador" => "sec0075"
                  "titulo" => "Grazoprevir&#47;elbasvir &#40;Zepatier&#44; MSD&#41;"
                ]
                2 => array:2 [
                  "identificador" => "sec0080"
                  "titulo" => "Sofosbuvir&#47;ledipasvir &#40;Harvoni&#44; Gilead&#41;"
                ]
                3 => array:2 [
                  "identificador" => "sec0085"
                  "titulo" => "Sofosbuvir&#47;velpatasvir &#40;Epclusa&#44; Gilead&#41;"
                ]
              ]
            ]
          ]
        ]
        8 => array:2 [
          "identificador" => "sec0090"
          "titulo" => "Indications for treatment"
        ]
        9 => array:2 [
          "identificador" => "sec0095"
          "titulo" => "Practical aspects of the treatment of chronic liver disease due to HCV"
        ]
        10 => array:2 [
          "identificador" => "sec0100"
          "titulo" => "Treatment regimens"
        ]
        11 => array:2 [
          "identificador" => "sec0105"
          "titulo" => "Conflict of interests"
        ]
        12 => array:1 [
          "titulo" => "References"
        ]
      ]
    ]
    "pdfFichero" => "main.pdf"
    "tienePdf" => true
    "fechaRecibido" => "2017-01-30"
    "fechaAceptado" => "2017-07-10"
    "PalabrasClave" => array:2 [
      "en" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec934100"
          "palabras" => array:2 [
            0 => "Hepatitis C virus"
            1 => "Direct-acting antivirals"
          ]
        ]
      ]
      "es" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec934101"
          "palabras" => array:2 [
            0 => "Virus de la hepatitis C"
            1 => "Antivirales de acci&#243;n directa"
          ]
        ]
      ]
    ]
    "tieneResumen" => true
    "resumen" => array:2 [
      "en" => array:2 [
        "titulo" => "Abstract"
        "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Hepatitis C virus infection is a significant public health problem&#46; The introduction of direct-acting antiviral agents&#44; whose efficacy is greater than 90&#37; in all patient groups &#40;including those with cirrhosis&#41;&#44; has represented a highly relevant change compared with classical interferon-based therapies&#46; Tolerance for these antiviral agents is significantly better&#44; and the treatment duration is shorter&#46; This review updates the treatment of hepatitis C virus infection with the new direct-acting antiviral agents&#46;</p></span>"
      ]
      "es" => array:2 [
        "titulo" => "Resumen"
        "resumen" => "<span id="abst0010" class="elsevierStyleSection elsevierViewall"><p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">La infecci&#243;n por el virus de la hepatitis C constituye un problema importante de salud p&#250;blica&#46; La introducci&#243;n de los antivirales de acci&#243;n directa&#44; cuya eficacia es superior al 90&#37; en todos los grupos de pacientes&#44; incluidos los cirr&#243;ticos&#44; ha supuesto un cambio muy relevante respecto al tratamiento con las terapias cl&#225;sicas basadas en interfer&#243;n&#46; Adem&#225;s&#44; la tolerancia de estos antivirales es significativamente mejor&#44; y la duraci&#243;n del tratamiento m&#225;s corta&#46; Esta revisi&#243;n pretende actualizar el tratamiento de la infecci&#243;n por el virus hepatitis C con los nuevos antivirales de acci&#243;n directa&#46;</p></span>"
      ]
    ]
    "NotaPie" => array:1 [
      0 => array:2 [
        "etiqueta" => "&#9734;"
        "nota" => "<p class="elsevierStyleNotepara" id="npar0015">Please cite this article as&#58; Vivancos MJ&#44; Moreno A&#44; Quereda C&#46; Tratamiento del virus de la hepatitis C con antivirales de acci&#243;n directa&#58; Aspectos pr&#225;cticos y situaci&#243;n actual&#46; Rev Clin Esp&#46; 2018&#59;218&#58;29&#8211;37&#46;</p>"
      ]
    ]
    "multimedia" => array:4 [
      0 => array:7 [
        "identificador" => "fig0005"
        "etiqueta" => "Figure 1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr1.jpeg"
            "Alto" => 1528
            "Ancho" => 2353
            "Tamanyo" => 232489
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Replication cycle of hepatitis C virus and therapeutic targets&#46;</p>"
        ]
      ]
      1 => array:7 [
        "identificador" => "fig0010"
        "etiqueta" => "Figure 2"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr2.jpeg"
            "Alto" => 2058
            "Ancho" => 2489
            "Tamanyo" => 245623
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">Factors to consider when selecting the therapeutic regimen&#46;</p>"
        ]
      ]
      2 => array:7 [
        "identificador" => "fig0015"
        "etiqueta" => "Figure 3"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr3.jpeg"
            "Alto" => 2618
            "Ancho" => 2910
            "Tamanyo" => 652451
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">Characteristics of the various drug families for the hepatitis C virus&#46;</p>"
        ]
      ]
      3 => array:8 [
        "identificador" => "tbl0005"
        "etiqueta" => "Table 1"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at1"
            "detalle" => "Table "
            "rol" => "short"
          ]
        ]
        "tabla" => array:3 [
          "leyenda" => "<p id="spar0035" class="elsevierStyleSimplePara elsevierViewall">Abbreviations&#58; DAA&#44; direct-acting antivirals&#59; DCV&#44; daclatasvir&#59; DSV&#44; dasabuvir&#59; EBR&#44; elbasvir&#59; GZR&#44; grazoprevir&#59; HCV&#44; hepatitis C virus&#59; LDV&#44; ledipasvir&#59; OBV&#44; ombitasvir&#59; PI&#44; protease inhibitor&#59; PTV&#44; paritaprevir&#59; RBV&#44; ribavirin&#59; RTV&#44; ritonavir&#59; SOF&#44; sofosbuvir&#59; VEL&#44; velpatasvir&#59; VL&#44; baseline viral load of HCV&#59; w&#44; weeks of treatment&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Genotype&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Regimens&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Duration and special considerations&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="table-entry  " rowspan="4" align="left" valign="top">1a</td><td class="td" title="table-entry  " align="left" valign="top">SOF<span class="elsevierStyleHsp" style=""></span>&#43;<span class="elsevierStyleHsp" style=""></span>LDV&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Only 8<span class="elsevierStyleHsp" style=""></span>w&#58; for treatment-naive&#44; CV<span class="elsevierStyleHsp" style=""></span>&#8804;6<span class="elsevierStyleHsp" style=""></span>&#215;<span class="elsevierStyleHsp" style=""></span>10<span class="elsevierStyleSup">6</span><span class="elsevierStyleHsp" style=""></span>UI&#47;mL&#44; and no cirrhosis &#40;caution in F3&#41;<br>12<span class="elsevierStyleHsp" style=""></span>w without RBV&#58; naive with or without compensated cirrhosis&#59; pretreated patients<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">a</span></a> without compensated cirrhosis if there are no resistances in NS5A<br>12<span class="elsevierStyleHsp" style=""></span>w<span class="elsevierStyleHsp" style=""></span>&#43;<span class="elsevierStyleHsp" style=""></span>RBV&#58; for decompensated cirrhosis<br>For pretreated patients<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">a</span></a> with NS5A resistances or without being able to rule them out&#44; with or without cirrhosis<br>24<span class="elsevierStyleHsp" style=""></span>w&#58; for the previous case and contraindication for RBV<br>24<span class="elsevierStyleHsp" style=""></span>w<span class="elsevierStyleHsp" style=""></span>&#43;<span class="elsevierStyleHsp" style=""></span>RBV&#58; for patients with liver transplants and decompensated cirrhosis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">PTV&#47;RTV<span class="elsevierStyleHsp" style=""></span>&#43;<span class="elsevierStyleHsp" style=""></span>OBV<span class="elsevierStyleHsp" style=""></span>&#43;<span class="elsevierStyleHsp" style=""></span>DSV<span class="elsevierStyleHsp" style=""></span>&#43;<span class="elsevierStyleHsp" style=""></span>RBV&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">12<span class="elsevierStyleHsp" style=""></span>w&#58; for no cirrhosis&#59; 24<span class="elsevierStyleHsp" style=""></span>w&#58; for compensated cirrhosis<br>Should not be used for decompensated cirrhosis or for previous failures with PI&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">GZR<span class="elsevierStyleHsp" style=""></span>&#43;<span class="elsevierStyleHsp" style=""></span>EBR&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">12<span class="elsevierStyleHsp" style=""></span>w without RBV&#58; if there are no resistances to EBV or if CV &#8804;800&#44;000<span class="elsevierStyleHsp" style=""></span>IU&#47;mL<br>16<span class="elsevierStyleHsp" style=""></span>w<span class="elsevierStyleHsp" style=""></span>&#43;<span class="elsevierStyleHsp" style=""></span>RBV&#58; if there is resistance to EBV &#40;or test is not available&#41; and&#47;or CV &#62;800&#44;000<span class="elsevierStyleHsp" style=""></span>IU&#47;mL<br>Should not be used for decompensated cirrhosis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">SOF<span class="elsevierStyleHsp" style=""></span>&#43;<span class="elsevierStyleHsp" style=""></span>VEL&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">12<span class="elsevierStyleHsp" style=""></span>w<br>12<span class="elsevierStyleHsp" style=""></span>w<span class="elsevierStyleHsp" style=""></span>&#43;<span class="elsevierStyleHsp" style=""></span>RBV&#58; for decompensated cirrhosis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="3" align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="table-entry  " rowspan="4" align="left" valign="top">1b</td><td class="td" title="table-entry  " align="left" valign="top">SOF<span class="elsevierStyleHsp" style=""></span>&#43;<span class="elsevierStyleHsp" style=""></span>LDV&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Only 8<span class="elsevierStyleHsp" style=""></span>w&#58; for treatment-naive&#44; CV<span class="elsevierStyleHsp" style=""></span>&#8804;6<span class="elsevierStyleHsp" style=""></span>&#215;<span class="elsevierStyleHsp" style=""></span>10<span class="elsevierStyleSup">6</span><span class="elsevierStyleHsp" style=""></span>UI&#47;mL&#44; and no cirrhosis &#40;caution in F3&#41;<br>12<span class="elsevierStyleHsp" style=""></span>w without RBV&#58; naive with CV<span class="elsevierStyleHsp" style=""></span>&#62;6<span class="elsevierStyleHsp" style=""></span>&#215;<span class="elsevierStyleHsp" style=""></span>10<span class="elsevierStyleSup">6</span><span class="elsevierStyleHsp" style=""></span>IU&#47;mL or cirrhosis&#59; pretreated patients<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">a</span></a> without cirrhosis<br>12<span class="elsevierStyleHsp" style=""></span>w<span class="elsevierStyleHsp" style=""></span>&#43;<span class="elsevierStyleHsp" style=""></span>RBV&#58; in pretreated<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">a</span></a> compensated cirrhosis<a class="elsevierStyleCrossRef" href="#tblfn0010"><span class="elsevierStyleSup">b</span></a>&#59; in decompensated cirrhosis<br>24<span class="elsevierStyleHsp" style=""></span>w<span class="elsevierStyleHsp" style=""></span>&#43;<span class="elsevierStyleHsp" style=""></span>RBV&#58; for patients with liver transplants and decompensated cirrhosis<br>24<span class="elsevierStyleHsp" style=""></span>w without RBV&#58; if there is an indication for RBV and with contraindication for the same&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">PTV&#47;RTV<span class="elsevierStyleHsp" style=""></span>&#43;<span class="elsevierStyleHsp" style=""></span>OBV<span class="elsevierStyleHsp" style=""></span>&#43;<span class="elsevierStyleHsp" style=""></span>DSV&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">12<span class="elsevierStyleHsp" style=""></span>w without RBV<br>8<span class="elsevierStyleHsp" style=""></span>w without RBV&#58; for treatment-naive and no cirrhosis &#40;caution in F3&#41;<br>Should not be used for decompensated cirrhosis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">GZR<span class="elsevierStyleHsp" style=""></span>&#43;<span class="elsevierStyleHsp" style=""></span>EBR&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">12<span class="elsevierStyleHsp" style=""></span>w<br>Should not be used for decompensated cirrhosis<br>Add RBV if previous failure to PI&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">SOF<span class="elsevierStyleHsp" style=""></span>&#43;<span class="elsevierStyleHsp" style=""></span>VEL&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">12<span class="elsevierStyleHsp" style=""></span>w&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="3" align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="table-entry  " rowspan="3" align="left" valign="top">2</td><td class="td" title="table-entry  " align="left" valign="top">SOF<span class="elsevierStyleHsp" style=""></span>&#43;<span class="elsevierStyleHsp" style=""></span>RBV&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">12<span class="elsevierStyleHsp" style=""></span>w&#59; 24 s&#58; for cirrhosis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">SOF<span class="elsevierStyleHsp" style=""></span>&#43;<span class="elsevierStyleHsp" style=""></span>DCV&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">12<span class="elsevierStyleHsp" style=""></span>w&#58; scarce experience with this regimen&#59; add RBV&#58; for decompensated cirrhosis<br>16&#8211;24<span class="elsevierStyleHsp" style=""></span>w&#58; for compensated cirrhosis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">SOF<span class="elsevierStyleHsp" style=""></span>&#43;<span class="elsevierStyleHsp" style=""></span>VEL&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">12<span class="elsevierStyleHsp" style=""></span>w&#59; add RBV&#58; for decompensated cirrhosis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="3" align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="table-entry  " rowspan="2" align="left" valign="top">3</td><td class="td" title="table-entry  " align="left" valign="top">SOF<span class="elsevierStyleHsp" style=""></span>&#43;<span class="elsevierStyleHsp" style=""></span>DCV&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">12<span class="elsevierStyleHsp" style=""></span>w&#58; treatment-naive without cirrhosis&#59; for pretreated<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">a</span></a> only if no Y93H mutation<br>12<span class="elsevierStyleHsp" style=""></span>w with RBV&#58; for pretreated without cirrhosis and with the Y93H resistance mutation or with no available resistance test<br>24<span class="elsevierStyleHsp" style=""></span>w with RBV&#58; for compensated or decompensated cirrhosis<br>24<span class="elsevierStyleHsp" style=""></span>w&#58; if RBV is recommended and contraindication to receive it&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">SOF<span class="elsevierStyleHsp" style=""></span>&#43;<span class="elsevierStyleHsp" style=""></span>VEL&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">12<span class="elsevierStyleHsp" style=""></span>w&#58; for treatment-naive without cirrhosis&#59; for pretreated<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">a</span></a> or cirrhosis&#44; only if there is no Y93H mutation<br>12<span class="elsevierStyleHsp" style=""></span>w with RBV&#58; for pretreated patients<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">a</span></a> or those with cirrhosis and with the Y93H resistance mutation or with no available resistance test<br>24<span class="elsevierStyleHsp" style=""></span>w with RBV&#58; for compensated cirrhosis<br>24<span class="elsevierStyleHsp" style=""></span>w&#58; if RBV is recommended and contraindication to receive it&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="3" align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="table-entry  " rowspan="4" align="left" valign="top">4</td><td class="td" title="table-entry  " align="left" valign="top">SOF<span class="elsevierStyleHsp" style=""></span>&#43;<span class="elsevierStyleHsp" style=""></span>LDV&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">12<span class="elsevierStyleHsp" style=""></span>w&#58; treatment-naive<br>12<span class="elsevierStyleHsp" style=""></span>w<span class="elsevierStyleHsp" style=""></span>&#43;<span class="elsevierStyleHsp" style=""></span>RBV&#58; for pretreated patients<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">a</span></a> and for decompensated cirrhosis<br>24<span class="elsevierStyleHsp" style=""></span>w&#58; if RBV is recommended and contraindication to receive it&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">PTV&#47;RTV<span class="elsevierStyleHsp" style=""></span>&#43;<span class="elsevierStyleHsp" style=""></span>OBV<span class="elsevierStyleHsp" style=""></span>&#43;<span class="elsevierStyleHsp" style=""></span>RBV&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">12<span class="elsevierStyleHsp" style=""></span>s &#43;&#47;&#8722; RBV &#40;if there are problems with RBV&#44; the regimen without RBV can be administered&#41;<br>Should not be used for decompensated cirrhosis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">GZR<span class="elsevierStyleHsp" style=""></span>&#43;<span class="elsevierStyleHsp" style=""></span>EBR&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">12<span class="elsevierStyleHsp" style=""></span>w<br>16<span class="elsevierStyleHsp" style=""></span>s with RBV&#58; assess this regimen in pretreated patients<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">a</span></a> and CV &#60;800&#44;000<span class="elsevierStyleHsp" style=""></span>IU&#47;mL<br>Should not be used for decompensated cirrhosis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">SOF<span class="elsevierStyleHsp" style=""></span>&#43;<span class="elsevierStyleHsp" style=""></span>VEL&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">12<span class="elsevierStyleHsp" style=""></span>w<br>12<span class="elsevierStyleHsp" style=""></span>w with RBV&#58; for decompensated cirrhosis<br>24<span class="elsevierStyleHsp" style=""></span>s&#58; in decompensated cirrhosis and contraindication for RBV&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab1633349.png"
              ]
            ]
          ]
          "notaPie" => array:2 [
            0 => array:3 [
              "identificador" => "tblfn0005"
              "etiqueta" => "a"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Pretreated refers to a previous failure with regimens with interferon and RBV&#43;&#47;&#8722; first-generation PI&#46; For failures with DAA&#44; consult an expert&#46;</p>"
            ]
            1 => array:3 [
              "identificador" => "tblfn0010"
              "etiqueta" => "b"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0010">The European guidelines recommend 12 weeks without RBV&#44; while the American guidelines recommend 12 weeks with RBV&#46;</p>"
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">Treatment regimens for chronic hepatitis C virus infection according to genotype&#46;</p>"
        ]
      ]
    ]
    "bibliografia" => array:2 [
      "titulo" => "References"
      "seccion" => array:1 [
        0 => array:2 [
          "identificador" => "bibs0015"
          "bibliografiaReferencia" => array:36 [
            0 => array:3 [
              "identificador" => "bib0185"
              "etiqueta" => "1"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Global epidemiology of hepatitis C virus infection&#58; new estimates of age-specific antibody to HCV seroprevalence"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "K&#46; Mohd Hanafiah"
                            1 => "J&#46; Groeger"
                            2 => "A&#46;D&#46; Flaxman"
                            3 => "S&#46;T&#46; Wiersma"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1002/hep.26141"
                      "Revista" => array:6 [
                        "tituloSerie" => "Hepatology"
                        "fecha" => "2013"
                        "volumen" => "57"
                        "paginaInicial" => "1333"
                        "paginaFinal" => "1342"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23172780"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "bib0190"
              "etiqueta" => "2"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Global distribution and prevalence of hepatitis C virus genotypes"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "J&#46;P&#46; Messina"
                            1 => "I&#46; Humphreys"
                            2 => "A&#46; Flaxman"
                            3 => "A&#46; Brown"
                            4 => "G&#46;S&#46; Cooke"
                            5 => "O&#46;G&#46; Pybus"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Hematology"
                        "fecha" => "2015"
                        "volumen" => "61"
                        "paginaInicial" => "77"
                        "paginaFinal" => "87"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            2 => array:3 [
              "identificador" => "bib0195"
              "etiqueta" => "3"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Aging of hepatitis C virus &#40;HCV&#41;-infected persons in the United States&#58; a multiple cohort model of HCV prevalence and disease progression"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "G&#46;L&#46; Davis"
                            1 => "M&#46;J&#46; Alter"
                            2 => "H&#46; El-Serag"
                            3 => "T&#46; Poynard"
                            4 => "L&#46;W&#46; Jennings"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1053/j.gastro.2009.09.067"
                      "Revista" => array:6 [
                        "tituloSerie" => "Gastroenterology"
                        "fecha" => "2010"
                        "volumen" => "138"
                        "paginaInicial" => "513"
                        "paginaFinal" => "514"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19861128"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            3 => array:3 [
              "identificador" => "bib0200"
              "etiqueta" => "4"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Epidemiology and natural history of HCV infection"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "B&#46; Hajarizadeh"
                            1 => "J&#46; Grebely"
                            2 => "G&#46;J&#46; Dore"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Nat Rev Gastroenterol Hepat"
                        "fecha" => "2013"
                        "volumen" => "10"
                        "paginaInicial" => "553"
                        "paginaFinal" => "562"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            4 => array:3 [
              "identificador" => "bib0205"
              "etiqueta" => "5"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010&#58; a systematic analysis for the Global Burden of Disease Study 2010"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "R&#46; Lozano"
                            1 => "M&#46; Naghavi"
                            2 => "K&#46; Foreman"
                            3 => "S&#46; Lim"
                            4 => "K&#46; Shibuya"
                            5 => "V&#46; Aboyans"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/S0140-6736(12)61728-0"
                      "Revista" => array:6 [
                        "tituloSerie" => "Lancet"
                        "fecha" => "2012"
                        "volumen" => "380"
                        "paginaInicial" => "2095"
                        "paginaFinal" => "2128"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23245604"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            5 => array:3 [
              "identificador" => "bib0210"
              "etiqueta" => "6"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "S&#46; Maylin"
                            1 => "M&#46; Martinot-Peignoux"
                            2 => "R&#46; Moucari"
                            3 => "N&#46; Boyer"
                            4 => "M&#46;P&#46; Ripault"
                            5 => "D&#46; Cazals-Hatem"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1053/j.gastro.2008.05.044"
                      "Revista" => array:6 [
                        "tituloSerie" => "Gastroenterology"
                        "fecha" => "2008"
                        "volumen" => "135"
                        "paginaInicial" => "821"
                        "paginaFinal" => "829"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18593587"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            6 => array:3 [
              "identificador" => "bib0215"
              "etiqueta" => "7"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Improvement of liver function parameters in advanced HCV-associated liver cirrhosis by IFN-free antiviral therapies"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "K&#46; Deterding"
                            1 => "C&#46; Honer Zu Siederdissen"
                            2 => "K&#46; Port"
                            3 => "P&#46; Solbach"
                            4 => "L&#46; Sollik"
                            5 => "J&#46; Kirschner"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/apt.13343"
                      "Revista" => array:6 [
                        "tituloSerie" => "Aliment Pharmacol Ther"
                        "fecha" => "2015"
                        "volumen" => "42"
                        "paginaInicial" => "889"
                        "paginaFinal" => "901"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26250762"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            7 => array:3 [
              "identificador" => "bib0220"
              "etiqueta" => "8"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "A brief history of the treatment of viral hepatitis C"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "D&#46;B&#46; Strader"
                            1 => "L&#46;B&#46; Seeff"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Clin Liver Dis"
                        "fecha" => "2012"
                        "volumen" => "1"
                        "paginaInicial" => "6"
                        "paginaFinal" => "11"
                        "itemHostRev" => array:3 [
                          "pii" => "S0140673608600744"
                          "estado" => "S300"
                          "issn" => "01406736"
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            8 => array:3 [
              "identificador" => "bib0225"
              "etiqueta" => "9"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "Recommendations for testing&#44; managing&#44; and treating hepatitis C&#46; American Association for the Study of Liver Diseases and the Infectious Diseases Society of America&#46; Available from&#58; <a href="http://www.hcvguidelines.org/">http&#58;&#47;&#47;www&#46;hcvguidelines&#46;org</a> &#91;accessed 11&#46;12&#46;16&#93;&#46;"
                ]
              ]
            ]
            9 => array:3 [
              "identificador" => "bib0230"
              "etiqueta" => "10"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "EASL recommendations on treatment of hepatitis C 2016"
                      "autores" => array:1 [
                        0 => array:2 [
                          "colaboracion" => "European Association for the Study of the Liver"
                          "etal" => false
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jhep.2016.09.001"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Hepatol"
                        "fecha" => "2017"
                        "volumen" => "66"
                        "paginaInicial" => "153"
                        "paginaFinal" => "194"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27667367"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            10 => array:3 [
              "identificador" => "bib0235"
              "etiqueta" => "11"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "Gu&#237;as AEEH&#47;SEIMC de manejo de la hepatitis C&#46; Available from&#58; <a href="http://aeeh.es/wp-content/uploads/2017/06/consenso.pdf">http&#58;&#47;&#47;aeeh&#46;es&#47;wp-content&#47;uploads&#47;2017&#47;06&#47;consenso&#46;pdf</a> &#91;accessed July 2017&#93;&#46;"
                ]
              ]
            ]
            11 => array:3 [
              "identificador" => "bib0240"
              "etiqueta" => "12"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Interaction of hepatitis C virus nonstructural protein 5A with core protein is critical for the production of infectious virus particles"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "T&#46; Masaki"
                            1 => "R&#46; Suzuki"
                            2 => "K&#46; Murakami"
                            3 => "H&#46; Aizaki"
                            4 => "K&#46; Ishii"
                            5 => "A&#46; Murayama"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1128/JVI.00826-08"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Virol"
                        "fecha" => "2008"
                        "volumen" => "82"
                        "paginaInicial" => "7964"
                        "paginaFinal" => "7976"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18524832"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            12 => array:3 [
              "identificador" => "bib0245"
              "etiqueta" => "13"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Biolog&#237;a molecular aplicada del virus de la hepatitis C"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "G&#46; Koutsoudakis"
                            1 => "X&#46; Forns"
                            2 => "S&#46; P&#233;rez del Pulgar"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.gastrohep.2012.11.005"
                      "Revista" => array:6 [
                        "tituloSerie" => "Gastroenterol Hepatol"
                        "fecha" => "2013"
                        "volumen" => "36"
                        "paginaInicial" => "280"
                        "paginaFinal" => "293"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23490024"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            13 => array:3 [
              "identificador" => "bib0250"
              "etiqueta" => "14"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Boceprevir for untreated chronic HCV genotype 1 infection"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "F&#46; Poordad"
                            1 => "J&#46; McCone Jr&#46;"
                            2 => "B&#46;R&#46; Bacon"
                            3 => "S&#46; Bruno"
                            4 => "M&#46;P&#46; Manns"
                            5 => "M&#46;S&#46; Sulkowski"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1056/NEJMoa1010494"
                      "Revista" => array:6 [
                        "tituloSerie" => "N Engl J Med"
                        "fecha" => "2011"
                        "volumen" => "364"
                        "paginaInicial" => "1195"
                        "paginaFinal" => "1206"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21449783"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            14 => array:3 [
              "identificador" => "bib0255"
              "etiqueta" => "15"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Telaprevir for previously untreated chronic hepatitis C virus infection"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "I&#46;M&#46; Jacobson"
                            1 => "J&#46;G&#46; McHutchison"
                            2 => "G&#46; Dusheiko"
                            3 => "A&#46;M&#46; di Bisceglie"
                            4 => "K&#46;R&#46; Reddy"
                            5 => "N&#46;H&#46; Bzowej"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "N Engl J Med"
                        "fecha" => "2011"
                        "volumen" => "23"
                        "paginaInicial" => "2405"
                        "paginaFinal" => "2416"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            15 => array:3 [
              "identificador" => "bib0260"
              "etiqueta" => "16"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "HEP Drug Interaction Checker&#44; Liverpool University&#46; Available from&#58; <a href="http://hep-druginteractions.org/">http&#58;&#47;&#47;hep-druginteractions&#46;org&#47;</a> &#91;accessed December 2017&#93;&#46;"
                ]
              ]
            ]
            16 => array:3 [
              "identificador" => "bib0265"
              "etiqueta" => "17"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "Zeuzem S&#44; Feld J&#44; Wang S&#44; Wang S&#44; Bourli&#232;re M&#44; Wedemeyer H&#44; et al&#46; ENDURANCE-1&#58; a phase 3 evaluation of the efficacy and safety of 8- versus 12-week treatment with glecaprevir&#47;pibrentasvir &#40;formerly ABT-493&#47;ABT-530&#41; in HCV genotype 1 infected patients with or without HIV-1 co-infection and without cirrhosis&#46; Presented at AASLD&#44; November 11&#8211;15&#44; 2016&#44; Boston&#44; MA&#46;"
                ]
              ]
            ]
            17 => array:3 [
              "identificador" => "bib0270"
              "etiqueta" => "18"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "Zeuzem S&#44; Flamm SL&#44; Tong M&#44; Vierling JM&#44; Pianko S&#44; Buggisch P&#44; et al&#46; A randomized&#44; controlled&#44; phase 3 trial of sofosbuvir&#47;velpatasvir&#47;voxilaprevir or sofosbuvir&#47;velpatasvir for 12 weeks in direct-acting antiviral-experienced patients with genotype 1-6 HCV infection&#58; the POLARIS-4 Study&#46; Presented at AASLD&#44; November 11&#8211;15&#44; 2016&#44; Boston&#44; MA&#46;"
                ]
              ]
            ]
            18 => array:3 [
              "identificador" => "bib0275"
              "etiqueta" => "19"
              "referencia" => array:1 [
                0 => array:3 [
                  "comentario" => "PMID&#58; <span class="elsevierStyleInterRef" id="intr0025" href="pmid:27353271">27353271</span>"
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Clinical resistance to velpatasvir &#40;GS-5816&#41;&#44; a novel pan-genotypic inhibitor of the hepatitis C virus NS5A protein"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "E&#46;J&#46; Lawitz"
                            1 => "H&#46; Dvory-Sobol"
                            2 => "B&#46;P&#46; Doehle"
                            3 => "A&#46;S&#46; Worth"
                            4 => "J&#46; McNally"
                            5 => "D&#46;M&#46; Brainard"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1128/AAC.00763-16"
                      "Revista" => array:6 [
                        "tituloSerie" => "Antimicrob Agents Chemother"
                        "fecha" => "2016"
                        "volumen" => "60"
                        "paginaInicial" => "5368"
                        "paginaFinal" => "5378"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27353271"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            19 => array:3 [
              "identificador" => "bib0280"
              "etiqueta" => "20"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Simeprevir with pegylated interferon alpha 2a or 2b plus ribavirin in treatment-na&#239;ve patients with chronic hepatitis C virus genotype 1 infection &#40;QUEST-2&#41;&#58; a randomised&#44; double-blind&#44; placebo-controlled phase 3 trial"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "M&#46; Manns"
                            1 => "P&#46; Marcellin"
                            2 => "F&#46; Poordad"
                            3 => "E&#46;S&#46; de Araujo"
                            4 => "M&#46; Buti"
                            5 => "Y&#46; Horsmans"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Lancet"
                        "fecha" => "2014"
                        "volumen" => "2"
                        "paginaInicial" => "414"
                        "paginaFinal" => "426"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/2569600"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            20 => array:3 [
              "identificador" => "bib0285"
              "etiqueta" => "21"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Simeprevir and sofosbuvir for treatment of chronic hepatitis C infection"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "L&#46;M&#46; Childs-Kean"
                            1 => "E&#46;O&#46; Hand"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.clinthera.2014.12.012"
                      "Revista" => array:6 [
                        "tituloSerie" => "Clin Ther"
                        "fecha" => "2015"
                        "volumen" => "37"
                        "paginaInicial" => "243"
                        "paginaFinal" => "267"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25601269"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            21 => array:3 [
              "identificador" => "bib0290"
              "etiqueta" => "22"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Daclatasvir plus simeprevir with or without ribavirin for the treatment of chronic hepatitis C virus genotype 1 infection"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "S&#46; Zeuzem"
                            1 => "C&#46; H&#233;zode"
                            2 => "J&#46;P&#46; Bronowicki"
                            3 => "V&#46; Loustaud-Ratti"
                            4 => "F&#46; Gea"
                            5 => "M&#46; Buti"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jhep.2015.09.024"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Hepatol"
                        "fecha" => "2016"
                        "volumen" => "64"
                        "paginaInicial" => "292"
                        "paginaFinal" => "300"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26453968"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            22 => array:3 [
              "identificador" => "bib0295"
              "etiqueta" => "23"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Simeprevir plus sofosbuvir&#44; with or without ribavirin&#44; to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-na&#239;ve patients&#58; the COSMOS randomised study"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "E&#46; Lawitz"
                            1 => "M&#46;S&#46; Sulkowski"
                            2 => "R&#46; Ghalib"
                            3 => "M&#46; Rodriguez-Torres"
                            4 => "Z&#46;M&#46; Younossi"
                            5 => "A&#46; Corregidor"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Lancet"
                        "fecha" => "2014"
                        "volumen" => "15"
                        "paginaInicial" => "1756"
                        "paginaFinal" => "1765"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            23 => array:3 [
              "identificador" => "bib0300"
              "etiqueta" => "24"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Update on hepatitis C virus resistance to direct-acting antiviral agents"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [
                            0 => "E&#46; Poveda"
                            1 => "D&#46;L&#46; Wyles"
                            2 => "A&#46; Mena"
                            3 => "J&#46;D&#46; Pedreira"
                            4 => "A&#46; Castro-Iglesias"
                            5 => "E&#46; Cachay"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.antiviral.2014.05.015"
                      "Revista" => array:6 [
                        "tituloSerie" => "Antiviral Res"
                        "fecha" => "2014"
                        "volumen" => "108"
                        "paginaInicial" => "181"
                        "paginaFinal" => "191"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24911972"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            24 => array:3 [
              "identificador" => "bib0305"
              "etiqueta" => "25"
              "referencia" => array:1 [
                0 => array:3 [
                  "comentario" => "Available from&#58; <span class="elsevierStyleInterRef" id="intr0030" href="https://www.olysio.com/shared/product/olysio/prescribing-information.pdf">https&#58;&#47;&#47;www&#46;olysio&#46;com&#47;shared&#47;product&#47;olysio&#47;prescribing-information&#46;pdf</span> &#91;accessed 11&#46;12&#46;16&#93;"
                  "contribucion" => array:1 [
                    0 => array:1 [
                      "titulo" => "Olysio &#40;simeprevir&#41; package insert"
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Libro" => array:3 [
                        "fecha" => "May 2016"
                        "editorial" => "Janssen Therapeutics"
                        "editorialLocalizacion" => "Titusville&#44; NJ"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            25 => array:3 [
              "identificador" => "bib0310"
              "etiqueta" => "26"
              "referencia" => array:1 [
                0 => array:3 [
                  "comentario" => "Available from&#58; <span class="elsevierStyleInterRef" id="intr0035" href="http://packageinserts.bms.com/pi/pi_daklinza.pdf">http&#58;&#47;&#47;packageinserts&#46;bms&#46;com&#47;pi&#47;pi&#95;daklinza&#46;pdf</span> &#91;accessed 11&#46;12&#46;16&#93;"
                  "contribucion" => array:1 [
                    0 => array:1 [
                      "titulo" => "Daklinza &#40;daclatasvir&#41; prescribing information"
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Libro" => array:3 [
                        "fecha" => "February 2016"
                        "editorial" => "Bristol-Myers Squibb Co&#46;"
                        "editorialLocalizacion" => "Princeton&#44; NJ"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            26 => array:3 [
              "identificador" => "bib0315"
              "etiqueta" => "27"
              "referencia" => array:1 [
                0 => array:3 [
                  "comentario" => "Available from&#58; <span class="elsevierStyleInterRef" id="intr0040" href="http://www.gilead.ca/pdf/ca/sovaldi_pm_english.pdf">http&#58;&#47;&#47;www&#46;gilead&#46;ca&#47;pdf&#47;ca&#47;sovaldi&#95;pm&#95;english&#46;pdf</span> &#91;accessed 11&#46;12&#46;16&#93;"
                  "contribucion" => array:1 [
                    0 => array:1 [
                      "titulo" => "Sovaldi &#40;sofosbuvir&#41; product monograph"
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Libro" => array:3 [
                        "fecha" => "July 2015"
                        "editorial" => "Gilead Sciences Canada&#44; Inc&#46;"
                        "editorialLocalizacion" => "Mississauga&#44; Ontario&#44; Canada"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            27 => array:3 [
              "identificador" => "bib0320"
              "etiqueta" => "28"
              "referencia" => array:1 [
                0 => array:3 [
                  "comentario" => "Available from&#58; <span class="elsevierStyleInterRef" id="intr0045" href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206619lbl.pdf">https&#58;&#47;&#47;www&#46;accessdata&#46;fda&#46;gov&#47;drugsatfda&#95;docs&#47;label&#47;2014&#47;206619lbl&#46;pdf</span> &#91;accessed 11&#46;12&#46;16&#93;"
                  "contribucion" => array:1 [
                    0 => array:1 [
                      "titulo" => "Viekira Pak &#40;ombitasvir&#44; paritaprevir&#44; ritonavir&#44; dasabuvir&#41; prescribing information"
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Libro" => array:3 [
                        "fecha" => "June 2016"
                        "editorial" => "AbbVie Inc&#46;"
                        "editorialLocalizacion" => "North Chicago&#44; IL"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            28 => array:3 [
              "identificador" => "bib0325"
              "etiqueta" => "29"
              "referencia" => array:1 [
                0 => array:3 [
                  "comentario" => "Available from&#58; <span class="elsevierStyleInterRef" id="intr0050" href="https://www.merck.com/product/usa/pi_circulars/z/zepatier/zepatier_pi.pdf">https&#58;&#47;&#47;www&#46;merck&#46;com&#47;product&#47;usa&#47;pi&#95;circulars&#47;z&#47;zepatier&#47;zepatier&#95;pi&#46;pdf</span> &#91;accessed 11&#46;12&#46;16&#93;"
                  "contribucion" => array:1 [
                    0 => array:1 [
                      "titulo" => "Zepatier &#40;elbasvir and grazoprevir&#41; prescribing information"
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Libro" => array:3 [
                        "fecha" => "January 2016"
                        "editorial" => "Merck Sharp &#38; Dohme Corp&#46;"
                        "editorialLocalizacion" => "Whitehouse Station&#44; NJ"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            29 => array:3 [
              "identificador" => "bib0330"
              "etiqueta" => "30"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease"
                      "autores" => array:1 [
                        0 => array:3 [
                          "colaboracion" => "SOLAR-1 investigators"
                          "etal" => true
                          "autores" => array:6 [
                            0 => "M&#46; Charlton"
                            1 => "G&#46;T&#46; Everson"
                            2 => "S&#46;L&#46; Flamm"
                            3 => "P&#46; Kumar"
                            4 => "C&#46; Landis"
                            5 => "R&#46;S&#46; Brown Jr&#46;"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1053/j.gastro.2015.05.010"
                      "Revista" => array:6 [
                        "tituloSerie" => "Gastroenterology"
                        "fecha" => "2015"
                        "volumen" => "149"
                        "paginaInicial" => "649"
                        "paginaFinal" => "659"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25985734"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            30 => array:3 [
              "identificador" => "bib0335"
              "etiqueta" => "31"
              "referencia" => array:1 [
                0 => array:3 [
                  "comentario" => "Available from&#58; <span class="elsevierStyleInterRef" id="intr0055" href="https://www.gilead.com/~/media/Files/pdfs/medicines/liver-disease/harvoni/harvoni_pi.pdf">https&#58;&#47;&#47;www&#46;gilead&#46;com&#47;&#8764;&#47;media&#47;Files&#47;pdfs&#47;medicines&#47;liver-disease&#47;harvoni&#47;harvoni&#95;pi&#46;pdf</span> &#91;accessed 11&#46;12&#46;16&#93;"
                  "contribucion" => array:1 [
                    0 => array:1 [
                      "titulo" => "Harvoni &#40;ledipasvir&#47;sofosbuvir&#41; prescribing information"
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Libro" => array:3 [
                        "fecha" => "June 2016"
                        "editorial" => "Gilead Sciences Inc&#46;"
                        "editorialLocalizacion" => "Foster City&#44; CA"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            31 => array:3 [
              "identificador" => "bib0340"
              "etiqueta" => "32"
              "referencia" => array:1 [
                0 => array:3 [
                  "comentario" => "Available from&#58; <span class="elsevierStyleInterRef" id="intr0060" href="https://www.gilead.com/~/media/files/pdfs/medicines/liver-disease/epclusa/epclusa_pi.pdf">https&#58;&#47;&#47;www&#46;gilead&#46;com&#47;&#8764;&#47;media&#47;files&#47;pdfs&#47;medicines&#47;liver-disease&#47;epclusa&#47;epclusa&#95;pi&#46;pdf</span> &#91;accessed 11&#46;12&#46;16&#93;"
                  "contribucion" => array:1 [
                    0 => array:1 [
                      "titulo" => "Epclusa &#40;sofosbuvir and velpatasvir&#41; prescribing information"
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Libro" => array:3 [
                        "fecha" => "June 2016"
                        "editorial" => "Gilead Sciences Inc&#46;"
                        "editorialLocalizacion" => "Foster City&#44; CA"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            32 => array:3 [
              "identificador" => "bib0345"
              "etiqueta" => "33"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease&#58; analysis of data from the Hepa-C registry"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "C&#46; Fern&#225;ndez-Carrillo"
                            1 => "S&#46; Lens"
                            2 => "E&#46; Llop"
                            3 => "J&#46;M&#46; Pascasio"
                            4 => "J&#46; Crespo"
                            5 => "J&#46; Arenas"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1002/hep.29097"
                      "Revista" => array:6 [
                        "tituloSerie" => "Hepatology"
                        "fecha" => "2017"
                        "volumen" => "65"
                        "paginaInicial" => "1810"
                        "paginaFinal" => "1822"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28170112"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            33 => array:3 [
              "identificador" => "bib0350"
              "etiqueta" => "34"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Achieving sustained virological response&#58; what&#39;s the impact on further hepatitis C virus-related disease&#63;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:1 [
                            0 => "A&#46;J&#46; Van der Meer"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1586/17474124.2015.1001366"
                      "Revista" => array:6 [
                        "tituloSerie" => "Expert Rev Gastroenterol Hepatol"
                        "fecha" => "2015"
                        "volumen" => "9"
                        "paginaInicial" => "559"
                        "paginaFinal" => "566"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25579804"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            34 => array:3 [
              "identificador" => "bib0355"
              "etiqueta" => "35"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:1 [
                            0 => "J&#46;M&#46; Pawlotsky"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1053/j.gastro.2016.04.003"
                      "Revista" => array:6 [
                        "tituloSerie" => "Gastroenterology"
                        "fecha" => "2016"
                        "volumen" => "151"
                        "paginaInicial" => "70"
                        "paginaFinal" => "86"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27080301"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            35 => array:3 [
              "identificador" => "bib0360"
              "etiqueta" => "36"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Expanding consensus in portal hypertension&#58; report of the Baveno VI Consensus Workshop&#58; stratifying risk and individualizing care for portal hypertension"
                      "autores" => array:1 [
                        0 => array:3 [
                          "colaboracion" => "Baveno VI Faculty"
                          "etal" => false
                          "autores" => array:1 [
                            0 => "R&#46; De Franchis"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jhep.2015.05.022"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Hepatol"
                        "fecha" => "2015"
                        "volumen" => "63"
                        "paginaInicial" => "743"
                        "paginaFinal" => "752"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26047908"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
          ]
        ]
      ]
    ]
  ]
  "idiomaDefecto" => "en"
  "url" => "/22548874/0000021800000001/v1_201801040959/S2254887417301285/v1_201801040959/en/main.assets"
  "Apartado" => array:4 [
    "identificador" => "48740"
    "tipo" => "SECCION"
    "en" => array:2 [
      "titulo" => "Reviews"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "en"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/22548874/0000021800000001/v1_201801040959/S2254887417301285/v1_201801040959/en/main.pdf?idApp=WRCEE&text.app=https://revclinesp.es/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2254887417301285?idApp=WRCEE"
]
Share
Journal Information

Statistics

Follow this link to access the full text of the article

Review
Treatment of hepatitis C virus with direct-acting antivirals: Practical aspects and current situation
Tratamiento del virus de la hepatitis C con antivirales de acción directa: Aspectos prácticos y situación actual
M.J. Vivancos, A. Moreno, C. Quereda
Corresponding author
carmen.quereda@salud.madrid.org

Corresponding author.
Servicio de Enfermedades Infecciosas, Hospital Ramón y Cajal, Madrid, Spain
Read
15
Times
was read the article
8
Total PDF
7
Total HTML
Share statistics
 array:24 [
  "pii" => "S2254887417301285"
  "issn" => "22548874"
  "doi" => "10.1016/j.rceng.2017.07.005"
  "estado" => "S300"
  "fechaPublicacion" => "2018-01-01"
  "aid" => "1421"
  "copyright" => "Elsevier Espa&#241;a&#44; S&#46;L&#46;U&#46; and Sociedad Espa&#241;ola de Medicina Interna &#40;SEMI&#41;"
  "copyrightAnyo" => "2017"
  "documento" => "article"
  "crossmark" => 1
  "subdocumento" => "ssu"
  "cita" => "Rev Clin Esp. 2018;218:29-37"
  "abierto" => array:3 [
    "ES" => false
    "ES2" => false
    "LATM" => false
  ]
  "gratuito" => false
  "lecturas" => array:2 [
    "total" => 4
    "formatos" => array:2 [
      "HTML" => 2
      "PDF" => 2
    ]
  ]
  "Traduccion" => array:1 [
    "es" => array:18 [
      "pii" => "S0014256517301807"
      "issn" => "00142565"
      "doi" => "10.1016/j.rce.2017.07.006"
      "estado" => "S300"
      "fechaPublicacion" => "2018-01-01"
      "aid" => "1421"
      "documento" => "article"
      "crossmark" => 1
      "subdocumento" => "ssu"
      "cita" => "Rev Clin Esp. 2018;218:29-37"
      "abierto" => array:3 [
        "ES" => false
        "ES2" => false
        "LATM" => false
      ]
      "gratuito" => false
      "lecturas" => array:2 [
        "total" => 197
        "formatos" => array:2 [
          "HTML" => 143
          "PDF" => 54
        ]
      ]
      "es" => array:13 [
        "idiomaDefecto" => true
        "cabecera" => "<span class="elsevierStyleTextfn">Revisi&#243;n</span>"
        "titulo" => "Tratamiento del virus de la hepatitis<span class="elsevierStyleHsp" style=""></span>C con antivirales de acci&#243;n directa&#58; Aspectos pr&#225;cticos y situaci&#243;n actual"
        "tienePdf" => "es"
        "tieneTextoCompleto" => "es"
        "tieneResumen" => array:2 [
          0 => "es"
          1 => "en"
        ]
        "paginas" => array:1 [
          0 => array:2 [
            "paginaInicial" => "29"
            "paginaFinal" => "37"
          ]
        ]
        "titulosAlternativos" => array:1 [
          "en" => array:1 [
            "titulo" => "Treatment of hepatitis<span class="elsevierStyleHsp" style=""></span>C virus with direct-acting antivirals&#58; Practical aspects and current situation"
          ]
        ]
        "contieneResumen" => array:2 [
          "es" => true
          "en" => true
        ]
        "contieneTextoCompleto" => array:1 [
          "es" => true
        ]
        "contienePdf" => array:1 [
          "es" => true
        ]
        "resumenGrafico" => array:2 [
          "original" => 0
          "multimedia" => array:7 [
            "identificador" => "fig0010"
            "etiqueta" => "Figura 2"
            "tipo" => "MULTIMEDIAFIGURA"
            "mostrarFloat" => true
            "mostrarDisplay" => false
            "figura" => array:1 [
              0 => array:4 [
                "imagen" => "gr2.jpeg"
                "Alto" => 2058
                "Ancho" => 2489
                "Tamanyo" => 269207
              ]
            ]
            "descripcion" => array:1 [
              "es" => "<p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">Factores a tener en cuenta para la elecci&#243;n del r&#233;gimen terap&#233;utico&#46;</p>"
            ]
          ]
        ]
        "autores" => array:1 [
          0 => array:2 [
            "autoresLista" => "M&#46;J&#46; Vivancos, A&#46; Moreno, C&#46; Quereda"
            "autores" => array:3 [
              0 => array:2 [
                "nombre" => "M&#46;J&#46;"
                "apellidos" => "Vivancos"
              ]
              1 => array:2 [
                "nombre" => "A&#46;"
                "apellidos" => "Moreno"
              ]
              2 => array:2 [
                "nombre" => "C&#46;"
                "apellidos" => "Quereda"
              ]
            ]
          ]
        ]
      ]
      "idiomaDefecto" => "es"
      "Traduccion" => array:1 [
        "en" => array:9 [
          "pii" => "S2254887417301285"
          "doi" => "10.1016/j.rceng.2017.07.005"
          "estado" => "S300"
          "subdocumento" => ""
          "abierto" => array:3 [
            "ES" => false
            "ES2" => false
            "LATM" => false
          ]
          "gratuito" => false
          "lecturas" => array:1 [
            "total" => 0
          ]
          "idiomaDefecto" => "en"
          "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2254887417301285?idApp=WRCEE"
        ]
      ]
      "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0014256517301807?idApp=WRCEE"
      "url" => "/00142565/0000021800000001/v1_201801070655/S0014256517301807/v1_201801070655/es/main.assets"
    ]
  ]
  "itemSiguiente" => array:19 [
    "pii" => "S2254887417301200"
    "issn" => "22548874"
    "doi" => "10.1016/j.rceng.2017.10.002"
    "estado" => "S300"
    "fechaPublicacion" => "2018-01-01"
    "aid" => "1428"
    "copyright" => "Elsevier Espa&#241;a&#44; S&#46;L&#46;U&#46; and Sociedad Espa&#241;ola de Medicina Interna &#40;SEMI&#41;"
    "documento" => "article"
    "crossmark" => 1
    "subdocumento" => "sco"
    "cita" => "Rev Clin Esp. 2018;218:38-9"
    "abierto" => array:3 [
      "ES" => false
      "ES2" => false
      "LATM" => false
    ]
    "gratuito" => false
    "lecturas" => array:2 [
      "total" => 2
      "PDF" => 2
    ]
    "en" => array:11 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Medicine in images</span>"
      "titulo" => "Open thoracostomy as treatment of chronic empyema with bronchopleural fistula"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "38"
          "paginaFinal" => "39"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "Toracostom&#237;a abierta como tratamiento de un empiema cr&#243;nico con f&#237;stula broncopleural"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:6 [
          "identificador" => "fig0005"
          "etiqueta" => "Figure 1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "gr1.jpeg"
              "Alto" => 2077
              "Ancho" => 2500
              "Tamanyo" => 546253
            ]
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "M&#46;N&#46; Sol&#237;s-Marqu&#237;nez, J&#46;F&#46; L&#243;pez-Caleya"
          "autores" => array:2 [
            0 => array:2 [
              "nombre" => "M&#46;N&#46;"
              "apellidos" => "Sol&#237;s-Marqu&#237;nez"
            ]
            1 => array:2 [
              "nombre" => "J&#46;F&#46;"
              "apellidos" => "L&#243;pez-Caleya"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "Traduccion" => array:1 [
      "es" => array:9 [
        "pii" => "S0014256517301984"
        "doi" => "10.1016/j.rce.2017.08.001"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => false
          "ES2" => false
          "LATM" => false
        ]
        "gratuito" => false
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "es"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0014256517301984?idApp=WRCEE"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2254887417301200?idApp=WRCEE"
    "url" => "/22548874/0000021800000001/v1_201801040959/S2254887417301200/v1_201801040959/en/main.assets"
  ]
  "itemAnterior" => array:19 [
    "pii" => "S225488741730098X"
    "issn" => "22548874"
    "doi" => "10.1016/j.rceng.2017.09.001"
    "estado" => "S300"
    "fechaPublicacion" => "2018-01-01"
    "aid" => "1415"
    "copyright" => "Elsevier Espa&#241;a&#44; S&#46;L&#46;U&#46; and Sociedad Espa&#241;ola de Medicina Interna &#40;SEMI&#41;"
    "documento" => "article"
    "crossmark" => 1
    "subdocumento" => "ssu"
    "cita" => "Rev Clin Esp. 2018;218:22-8"
    "abierto" => array:3 [
      "ES" => false
      "ES2" => false
      "LATM" => false
    ]
    "gratuito" => false
    "lecturas" => array:2 [
      "total" => 2
      "PDF" => 2
    ]
    "en" => array:13 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Review</span>"
      "titulo" => "The pathophysiology of Fabry disease"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "tieneResumen" => array:2 [
        0 => "en"
        1 => "es"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "22"
          "paginaFinal" => "28"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "Fisiopatolog&#237;a de la enfermedad de Fabry"
        ]
      ]
      "contieneResumen" => array:2 [
        "en" => true
        "es" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:7 [
          "identificador" => "fig0005"
          "etiqueta" => "Figure 1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "gr1.jpeg"
              "Alto" => 1407
              "Ancho" => 3192
              "Tamanyo" => 200672
            ]
          ]
          "descripcion" => array:1 [
            "en" => "<p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Degradation pathway for complex lipids&#46;</p>"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "S&#46; Olivera-Gonz&#225;lez, C&#46; Josa-Laorden, M&#46;A&#46; Torralba-Cabeza"
          "autores" => array:3 [
            0 => array:2 [
              "nombre" => "S&#46;"
              "apellidos" => "Olivera-Gonz&#225;lez"
            ]
            1 => array:2 [
              "nombre" => "C&#46;"
              "apellidos" => "Josa-Laorden"
            ]
            2 => array:2 [
              "nombre" => "M&#46;A&#46;"
              "apellidos" => "Torralba-Cabeza"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "Traduccion" => array:1 [
      "es" => array:9 [
        "pii" => "S0014256517301571"
        "doi" => "10.1016/j.rce.2017.06.007"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => false
          "ES2" => false
          "LATM" => false
        ]
        "gratuito" => false
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "es"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0014256517301571?idApp=WRCEE"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S225488741730098X?idApp=WRCEE"
    "url" => "/22548874/0000021800000001/v1_201801040959/S225488741730098X/v1_201801040959/en/main.assets"
  ]
  "en" => array:20 [
    "idiomaDefecto" => true
    "cabecera" => "<span class="elsevierStyleTextfn">Review</span>"
    "titulo" => "Treatment of hepatitis C virus with direct-acting antivirals&#58; Practical aspects and current situation"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "29"
        "paginaFinal" => "37"
      ]
    ]
    "autores" => array:1 [
      0 => array:4 [
        "autoresLista" => "M&#46;J&#46; Vivancos, A&#46; Moreno, C&#46; Quereda"
        "autores" => array:3 [
          0 => array:2 [
            "nombre" => "M&#46;J&#46;"
            "apellidos" => "Vivancos"
          ]
          1 => array:2 [
            "nombre" => "A&#46;"
            "apellidos" => "Moreno"
          ]
          2 => array:4 [
            "nombre" => "C&#46;"
            "apellidos" => "Quereda"
            "email" => array:1 [
              0 => "carmen&#46;quereda&#64;salud&#46;madrid&#46;org"
            ]
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">&#42;</span>"
                "identificador" => "cor0005"
              ]
            ]
          ]
        ]
        "afiliaciones" => array:1 [
          0 => array:2 [
            "entidad" => "Servicio de Enfermedades Infecciosas&#44; Hospital Ram&#243;n y Cajal&#44; Madrid&#44; Spain"
            "identificador" => "aff0005"
          ]
        ]
        "correspondencia" => array:1 [
          0 => array:3 [
            "identificador" => "cor0005"
            "etiqueta" => "&#8270;"
            "correspondencia" => "Corresponding author&#46;"
          ]
        ]
      ]
    ]
    "titulosAlternativos" => array:1 [
      "es" => array:1 [
        "titulo" => "Tratamiento del virus de la hepatitis C con antivirales de acci&#243;n directa&#58; Aspectos pr&#225;cticos y situaci&#243;n actual"
      ]
    ]
    "resumenGrafico" => array:2 [
      "original" => 0
      "multimedia" => array:7 [
        "identificador" => "fig0005"
        "etiqueta" => "Figure 1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr1.jpeg"
            "Alto" => 1528
            "Ancho" => 2353
            "Tamanyo" => 232489
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Replication cycle of hepatitis C virus and therapeutic targets&#46;</p>"
        ]
      ]
    ]
    "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0025">Background</span><p id="par0005" class="elsevierStylePara elsevierViewall">The hepatitis C virus &#40;HCV&#41; affects more than 170 million individuals worldwide&#46;<a class="elsevierStyleCrossRefs" href="#bib0185"><span class="elsevierStyleSup">1&#44;2</span></a> HCV is the main cause of hepatic cirrhosis and hepatocarcinoma and is the most common indication for liver transplantation&#46;<a class="elsevierStyleCrossRefs" href="#bib0195"><span class="elsevierStyleSup">3&#44;4</span></a> Half a million individuals die every year from HCV-related liver disease&#46;<a class="elsevierStyleCrossRef" href="#bib0205"><span class="elsevierStyleSup">5</span></a></p><p id="par0010" class="elsevierStylePara elsevierViewall">The HCV genome does not integrate with that of the host&#44; and therefore its replication can be definitively inhibited&#44; curing the infection&#46; It has been shown that the sustained viral response &#40;SVR&#41; achieved with HCV treatment improves the histology and progression of liver disease&#46;<a class="elsevierStyleCrossRefs" href="#bib0210"><span class="elsevierStyleSup">6&#44;7</span></a> Chronic liver disease due to HCV began to be treated in 1991 with subcutaneous interferon alpha in monotherapy&#46; The efficacy of this treatment regimen was low&#44; and tolerance was poor&#46; In 1998&#44; ribavirin was included in the treatment&#44; improving the SVR rates but without significantly increasing the adverse effects of interferon&#46; In 2000&#44; conventional interferon alpha was replaced by pegylated interferon &#40;alpha 2a or alpha 2b&#41;&#44; improving the response and tolerance&#46; Neither interferon nor ribavirin have a direct antiviral effect against HCV but instead act by an immune-mediated mechanism&#46;</p><p id="par0015" class="elsevierStylePara elsevierViewall">Telaprevir and boceprevir&#44; the first direct-acting antivirals &#40;DAAs&#41; employed for treating chronic HCV infection&#44; were marketed in 2011&#46; Their mechanism of action inhibits the HCV protease &#40;PI&#41;&#46; These DAAs were approved for treatment in combination with pegylated interferon and ribavirin&#46;<a class="elsevierStyleCrossRef" href="#bib0220"><span class="elsevierStyleSup">8</span></a> Although this treatment regimen achieved a significant increase in the percentage of patients with SVR&#44; the regimen had significant limitations&#58; it was only effective for patients with genotype 1&#44; the treatment regimens were complex&#44; the number of pills were high&#44; the patients had intolerance or were contraindicated for interferon&#44; and the efficacy in subgroups with predictors of poor response continued to be low&#46;</p><p id="par0020" class="elsevierStylePara elsevierViewall">In 2013&#44; new DAAs began to appear&#44; which inhibited some of the steps in the virus replication cycle&#46; Using combinations of these drugs&#44; highly effective&#44; short and well-tolerated interferon-free treatment regimens have been achieved&#44; which have revolutionized HCV treatment&#44; even for patients with advanced stages of cirrhosis&#46;<a class="elsevierStyleCrossRefs" href="#bib0225"><span class="elsevierStyleSup">9&#8211;11</span></a></p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0030">Replication cycle of the hepatitis C virus&#46; Therapeutic targets</span><p id="par0025" class="elsevierStylePara elsevierViewall">HCV is an RNA virus of the <span class="elsevierStyleItalic">Flaviviridae</span> family&#46; To date&#44; 6 genotypes have been described &#40;1a&#47;1b&#44; 2&#44; 3&#44; 4&#44; 5 and 6&#41;&#46; In Europe and the United States&#44; the most common genotype is 1&#44; followed by genotypes 3 and 4&#46;<a class="elsevierStyleCrossRefs" href="#bib0185"><span class="elsevierStyleSup">1&#44;2</span></a> As with the human immunodeficiency virus &#40;HIV&#41;&#44; HCV has a high viral replication rate and a low error correction capability due to its polymerase RNA&#46; For patients with chronic infection&#44; these characteristics promote a considerable diversity of viral quasispecies&#46; However&#44; HCV does not integrate with the infected host&#39;s genome&#44; and HCV&#39;s entire cycle is performed in the cytoplasm&#46; Treatments that effectively block its replication can therefore eradicate the infection&#46; The replication cycle of HCV offers numerous therapeutic targets &#40;<a class="elsevierStyleCrossRef" href="#fig0005">Fig&#46; 1</a>&#41;&#46;</p><elsevierMultimedia ident="fig0005"></elsevierMultimedia><p id="par0030" class="elsevierStylePara elsevierViewall">The HCV virion enters the cells by endocytosis through a receptor&#46; HCV then releases its genome&#44; which is directed to the cell&#39;s endoplasmic reticulum&#44; where it forms a polyprotein of approximately 3011 amino acids through a translation process&#46; The HCV protease&#44; encoded by the NS3&#47;4A genome region&#44; is responsible &#40;along with other cell proteases&#41; for completing the hydrolysis of this polyprotein&#44; which is segmented into 3 structural and 7 nonstructural proteins&#46;<a class="elsevierStyleCrossRef" href="#bib0240"><span class="elsevierStyleSup">12</span></a> Inhibitors of this viral protease have been designed that bind to the viral&#39;s active center&#44; blocking its action and viral replication&#46; The composed proteins and the viral RNA interact with the NS5A protein&#44; which is associated with the membrane and is phosphorylated by a cell serine-kinase&#46; The NS5A protein has no known enzymatic function but is essential for RNA replication and the assembly of new viral particles&#46;<a class="elsevierStyleCrossRef" href="#bib0240"><span class="elsevierStyleSup">12</span></a> NS5A inhibitors block the binding with proteins and inhibit the relationship between the NS5A protein and the locations of HCV intracellular replication&#46;</p><p id="par0035" class="elsevierStylePara elsevierViewall">Moreover&#44; a nonstructural RNA-dependent RNA polymerase protein &#40;NS5B&#41; is also involved in viral RNA replication&#44; which produces a negative-strand RNA and serves as a mold for manufacturing positive-strand RNA&#46; The NS5B nucleoside analogues incorporate in the RNA and block the chain&#44; inhibiting HCV replication through the binding to the enzyme&#39;s catalytic site &#40;conserved&#41;&#46; This area is common in all genotypes&#59; the drugs that act on this target are therefore active against all genotypes &#40;pangenotypics&#41;&#46; In contrast&#44; non-nucleoside NS5B inhibitors are noncompetitive inhibitors&#44; which block RNA synthesis before the start of the chain and are more dependent on the viral genotype&#46;<a class="elsevierStyleCrossRef" href="#bib0240"><span class="elsevierStyleSup">12</span></a> The newly manufactured viral genomes can once again be replicated and translated or packaged to form new viral particles&#46; These new viral particles are released by exocytosis&#44; completing the cycle&#46;<a class="elsevierStyleCrossRef" href="#bib0245"><span class="elsevierStyleSup">13</span></a></p></span><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0035">Direct-acting antivirals&#46; Classification according to their mechanism of action</span><p id="par0040" class="elsevierStylePara elsevierViewall">The currently available DAAs are classified according to the target of the HCV replication cycle on which they act&#58;<ul class="elsevierStyleList" id="lis0005"><li class="elsevierStyleListItem" id="lsti0005"><span class="elsevierStyleLabel">-</span><p id="par0045" class="elsevierStylePara elsevierViewall">Protease inhibitors &#40;PI&#41; NS3&#47;4A&#46;</p></li><li class="elsevierStyleListItem" id="lsti0010"><span class="elsevierStyleLabel">-</span><p id="par0050" class="elsevierStylePara elsevierViewall">NS5A protein inhibitors&#46;</p></li><li class="elsevierStyleListItem" id="lsti0015"><span class="elsevierStyleLabel">-</span><p id="par0055" class="elsevierStylePara elsevierViewall">NS5B polymerase inhibitors&#44; which in turn can be nucleoside analogues and non-nucleoside analogues&#46;</p></li></ul></p><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0040">NS3&#47;4A protease inhibitors</span><p id="par0060" class="elsevierStylePara elsevierViewall">These agents act by inhibiting the HCV protease NS3&#47;4A and thereby the replication of the virus&#46; The drugs belonging to this family are named with the suffix &#8220;previr&#8221;&#46; Telaprevir and boceprevir were the first to be used and are therefore considered first-generation HCV PIs&#46;<a class="elsevierStyleCrossRefs" href="#bib0250"><span class="elsevierStyleSup">14&#44;15</span></a> Due to their above-mentioned limitations&#44; the drugs were replaced by other PIs&#46;</p><p id="par0065" class="elsevierStylePara elsevierViewall">The second and third-generation PIs&#44; which have been marketed&#44; are polygenotypic drugs with activity against the HCV genotypes 1&#44; 2 and 4 &#40;although the drugs are not used for HCV genotype 2&#41;&#46; However&#44; the drugs have no activity against genotype 3&#44; and there is little experience with genotypes 5 to 7&#46; Within genotype 1&#44; the drugs are more active against subtype 1b&#46; The first-generation PIs have greater potency&#44; safety&#44; tolerance and a longer half-life&#44; which allow them to be administered once a day with fewer drug interactions&#46; Nevertheless&#44; potential interactions should be checked&#44; and the patient should be instructed not to take any new drug without a previous consultation&#46;<a class="elsevierStyleCrossRef" href="#bib0260"><span class="elsevierStyleSup">16</span></a> Although resistant mutations can be generated in patients treated with these drugs&#44; the genetic barrier of these drugs to resistance is much greater than that of first-generation PIs&#46; The resistance mutations generated during treatment with some of these drugs does not jeopardize the response with other drugs of the same family&#46;</p><p id="par0070" class="elsevierStylePara elsevierViewall">The currently approved HCV PIs in Europe and the US are simeprevir&#44; paritaprevir &#40;which are administered boosted with ritonavir&#41; and grazoprevir&#46; Glecaprevir &#40;AbbVie&#41;<a class="elsevierStyleCrossRef" href="#bib0265"><span class="elsevierStyleSup">17</span></a> and voxilaprevir &#40;Gilead&#41;<a class="elsevierStyleCrossRef" href="#bib0270"><span class="elsevierStyleSup">18</span></a> are 2 potent new-generation pangenotypic PIs&#44; with activity against genotype 3 and are currently in advanced phases of research&#46;</p></span><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0045">NS5A inhibitors</span><p id="par0075" class="elsevierStylePara elsevierViewall">These drugs act by inhibiting the NS5A replication complex&#46; The drugs that belong to this family are pangenotypic and are named with the suffix &#8220;asvir&#8221;&#46; As with the PIs&#44; the drugs have greater activity within genotype 1 against subtype 1b&#46; The drugs are potent&#44; well-tolerated and have pharmacokinetics that allows for administration once a day&#46; Their adverse effects are generally mild&#46; Although these drugs generally have fewer interactions than PIs&#44; the interactions should always be considered when these drugs are used concomitantly with other drugs&#46;<a class="elsevierStyleCrossRef" href="#bib0260"><span class="elsevierStyleSup">16</span></a></p><p id="par0080" class="elsevierStylePara elsevierViewall">The currently approved NS5A inhibitors in Europe and the US are daclatasvir&#44; ombitasvir&#44; ledipasvir&#44; velpatasvir and elbasvir&#46; All but the first are coformulated with another DAA&#46; Pibrentasvir is a new NS5A inhibitor&#44; which will be used coformulated with glecaprevir &#40;AbbVie&#41;&#46;<a class="elsevierStyleCrossRef" href="#bib0265"><span class="elsevierStyleSup">17</span></a> The drug is still being researched&#44; but the results from phase III studies have been presented&#44; with excellent results in all genotypes&#44; without needing to add ribavirin&#46;<a class="elsevierStyleCrossRef" href="#bib0265"><span class="elsevierStyleSup">17</span></a></p><p id="par0085" class="elsevierStylePara elsevierViewall">The genetic barrier of this family of drugs is moderate&#46; Resistance mutations are frequently selected in patients who fail a treatment regimen that includes one of these drugs&#46; This possibility is lower with more modern NS5A inhibitors &#40;velpatasvir&#44; elbasvir and pibrentasvir&#41;&#46;<a class="elsevierStyleCrossRef" href="#bib0275"><span class="elsevierStyleSup">19</span></a></p></span><span id="sec0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0050">NS5B polymerase inhibitors</span><p id="par0090" class="elsevierStylePara elsevierViewall">These drugs act by inhibiting the HCV RNA polymerase NS5B&#46; Drugs belonging to this family are named with the suffix &#8220;buvir&#8221;&#46; There are 2 types of these drugs&#58; nucleoside analogues and non-nucleoside analogues&#46; We currently only have sofosbuvir in the first group and dasabuvir in the second&#46;</p><p id="par0095" class="elsevierStylePara elsevierViewall">The general characteristics of NS5B nucleoside analogue polymerase inhibitors are as follows&#58; &#40;1&#41; high antiviral potency&#59; &#40;2&#41; high barrier to resistance&#59; &#40;3&#41; pangenotypics&#59; &#40;4&#41; easy posology&#44; and &#40;5&#41; few adverse effects and interactions&#46; These characteristics make the drugs attractive as components of any treatment regimen&#46; In contrast&#44; NS5B non-nucleoside analogue polymerase inhibitors&#44; although safe and well-tolerated&#44; have low antiviral potency&#44; limited activity against genotype 1 and a low genetic barrier&#44; which frequently results in the appearance of strains with resistance mutations in the therapeutic failures&#46;</p></span></span><span id="sec0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0055">Characteristics of the available drugs for HCV treatment</span><span id="sec0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0060">Drugs without coformulation</span><span id="sec0045" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0065">Simeprevir &#40;Olysio<span class="elsevierStyleSup">&#174;</span>&#44; Janssen&#41;</span><p id="par0100" class="elsevierStylePara elsevierViewall">This is a second-generation HCV PI that is effective in patients with genotypes 1 and 4&#46; Dosages of 150<span class="elsevierStyleHsp" style=""></span>mg a day are employed&#44; in 12 to 24-week regimens&#46; There is experience with the use of simeprevir combined with pegylated interferon and ribavirin&#44;<a class="elsevierStyleCrossRef" href="#bib0280"><span class="elsevierStyleSup">20</span></a> with sofosbuvir<a class="elsevierStyleCrossRef" href="#bib0285"><span class="elsevierStyleSup">21</span></a> and with daclatasvir&#46;<a class="elsevierStyleCrossRef" href="#bib0290"><span class="elsevierStyleSup">22</span></a> When combined with sofosbuvir&#44; simeprevir has shown SVR rates of more than 80&#37;&#59; the combination with ribavirin does not improve the results&#46;<a class="elsevierStyleCrossRef" href="#bib0295"><span class="elsevierStyleSup">23</span></a> When combined with daclatasvir&#44; the results are unsatisfactory&#44; and there is very little experience with this combination&#46; The response rates with simeprevir are lower in patients with genotype 1 and the Q80K mutation&#44; especially in regimens in which it is combined with interferon and ribavirin&#46;<a class="elsevierStyleCrossRef" href="#bib0280"><span class="elsevierStyleSup">20</span></a> The drug is not recommended for patients who have previously failed regimens with an HCV PI&#46;<a class="elsevierStyleCrossRef" href="#bib0300"><span class="elsevierStyleSup">24</span></a></p><p id="par0105" class="elsevierStylePara elsevierViewall">Simeprevir is a very well-tolerated drug&#44; with generally mild adverse effects&#46; The most common adverse effects include skin rashes&#44; photosensitivity and increased transaminase and bilirubin levels&#46;<a class="elsevierStyleCrossRef" href="#bib0305"><span class="elsevierStyleSup">25</span></a> The drug is not recommended for patients with advanced liver disease &#40;Child&#8211;Pugh classes B and C&#41;&#44; because the disease can increase its serum levels and its toxicity&#46; Interactions can occur with other cytochrome P450 3A inducers and inhibitors&#46;</p><p id="par0110" class="elsevierStylePara elsevierViewall">Due to its lower potency&#44; potential drug interactions and lack of coformulation with other agents against HCV&#44; simeprevir is rarely used and has been displaced by other options&#46; The drug can still have a certain usefulness for the few patients for whom other regimens with DAA fail&#46;<a class="elsevierStyleCrossRef" href="#bib0300"><span class="elsevierStyleSup">24</span></a></p></span><span id="sec0050" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0070">Daclatasvir &#40;Daklinza<span class="elsevierStyleSup">&#174;</span>&#44; BMS&#41;</span><p id="par0115" class="elsevierStylePara elsevierViewall">This drug is a first-generation NS5A protein inhibitor&#44; active against genotypes 1 to 6&#46; Dosages of 60<span class="elsevierStyleHsp" style=""></span>mg a day are employed&#44; in 12 to 24-week regimens&#46; The dose must be reduced to 30<span class="elsevierStyleHsp" style=""></span>mg when used with atazanavir-ritonavir&#44; azole or clarithromycin&#46; If used along with efavirenz&#44; etravirine or dexamethasone&#44; the dosage should be increased to 90<span class="elsevierStyleHsp" style=""></span>mg a day&#46;<a class="elsevierStyleCrossRef" href="#bib0310"><span class="elsevierStyleSup">26</span></a> Although there is experience with the drug combined with various DAAs&#44; the most studied and effective regimen is the combination with sofosbuvir&#44; with or without ribavirin&#46; Despite its safety and efficacy&#44; the regimen is not a first-choice regimen&#44; because there are other more comfortable options with better cost-efficiency&#46;</p></span><span id="sec0055" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0075">Sofosbuvir &#40;Sovaldi<span class="elsevierStyleSup">&#174;</span>&#44; Gilead&#41;</span><p id="par0120" class="elsevierStylePara elsevierViewall">This is an NS5B polymerase inhibitor of the HCV nucleoside analogue and has shown its potent antiviral pangenotypic activity&#46; The drug is effective when combined with other DAAs and when combined with ribavirin in genotype 2&#46; Unlike PIs and NS5A inhibitors and within genotype 1&#44; the drug is more effective against 1a&#46; Its dosage is 400<span class="elsevierStyleHsp" style=""></span>mg once a day&#44; in 8 to 24-week regimens&#46;<a class="elsevierStyleCrossRef" href="#bib0315"><span class="elsevierStyleSup">27</span></a> Sofosbuvir is a safe drug&#44; with few interaction problems&#44; but is not recommended for patients with an estimated glomerular filtration rate &#60;30<span class="elsevierStyleHsp" style=""></span>mL&#47;min&#47;1&#46;73<span class="elsevierStyleHsp" style=""></span>m<span class="elsevierStyleSup">2</span>&#46; One of the drug&#39;s most distinctive features is its high genetic barrier&#44; with no reports of selection of resistant mutations after failures&#46;<a class="elsevierStyleCrossRef" href="#bib0315"><span class="elsevierStyleSup">27</span></a> This feature makes the drug essential for rescue treatments&#46;</p></span><span id="sec0060" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0080">Ribavirin</span><p id="par0125" class="elsevierStylePara elsevierViewall">Although not a DAA&#44; ribavirin is still used for treating HCV&#44; when combined with other drugs&#46;<a class="elsevierStyleCrossRef" href="#bib0235"><span class="elsevierStyleSup">11</span></a> The drug is used at dosages of 800 to 1200<span class="elsevierStyleHsp" style=""></span>mg a day&#44; adjusted for weight and renal function&#44; in 2 separate doses&#46; Its current use is limited as a supplementary drug in DAA combinations that have shown increased efficacy&#46; Ribavirin&#39;s main adverse effect is hemolytic anemia&#46;</p></span></span><span id="sec0065" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0085">Coformulated drugs</span><span id="sec0070" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0090">Paritaprevir&#47;ritonavir&#47;ombitasvir &#40;Viekirax<span class="elsevierStyleSup">&#174;</span>&#44; Abbvie&#41; with or without dasabuvir &#40;Exviera<span class="elsevierStyleSup">&#174;</span>&#44; Abbvie&#41;</span><p id="par0130" class="elsevierStylePara elsevierViewall">These drugs are known as the Abbvie 2D and 3D combos&#46; The first drug combines a ritonavir-boosted HCV PI &#40;paritaprevir&#41; and an NS5A inhibitor &#40;ombitasvir&#41; in a single pill&#46; The dosage is 2 tablets once a day&#46; The drug is indicated for the treatment of patients with genotypes 1 and 4&#46; For patients with genotype 1&#44; the drug is combined with dasabuvir&#59; if the genotype is 1a&#44; ribavirin is also added&#46; Dasabuvir is not used for patients with genotype 4 but is combined with ribavirin&#46;<a class="elsevierStyleCrossRef" href="#bib0320"><span class="elsevierStyleSup">28</span></a></p><p id="par0135" class="elsevierStylePara elsevierViewall">Reviewing all potential interactions is recommended before starting treatment&#46; If the patient is HIV positive&#44; it is important that the HIV viral load be undetectable with its antiretroviral therapy before starting this regimen that includes ritonavir&#44; to prevent the development of resistances&#46;<a class="elsevierStyleCrossRef" href="#bib0320"><span class="elsevierStyleSup">28</span></a> An adjustment is not necessary in the event of renal failure&#46; The drug should not be used in patients with advanced liver disease &#40;Child&#8211;Pugh classes B and C&#41;<a class="elsevierStyleCrossRef" href="#bib0320"><span class="elsevierStyleSup">28</span></a> or in patients who have previously failed regimens with other PIs&#46;<a class="elsevierStyleCrossRef" href="#bib0320"><span class="elsevierStyleSup">28</span></a></p><p id="par0140" class="elsevierStylePara elsevierViewall">Dasabuvir is a non-nucleoside analogue polymerase inhibitor of HCV and is only active against genotype 1&#46; The drug has less potency than other DAAs and is therefore always used in combination with paritaprevir&#47;ritonavir and ombitasvir&#46; Dasabuvir is well tolerated and safe and is administered every 12<span class="elsevierStyleHsp" style=""></span>h&#46;</p><p id="par0145" class="elsevierStylePara elsevierViewall">The combination of paritaprevir&#47;ritonavir&#44; ombitasvir and dasabuvir for treating HCV is considered a safe and well-tolerated regimen&#44; with a high success rate &#40;greater than 90&#37;&#41; and a lower cost than other therapeutic options&#46; The combination has also been shown safe in renal failure and does not require dose adjustment&#46; However&#44; its disadvantages are the larger number of pills than other therapeutic options&#44; the need for twice daily administration and the larger number of drug interactions&#46;<a class="elsevierStyleCrossRef" href="#bib0260"><span class="elsevierStyleSup">16</span></a></p></span><span id="sec0075" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0095">Grazoprevir&#47;elbasvir &#40;Zepatier<span class="elsevierStyleSup">&#174;</span>&#44; MSD&#41;</span><p id="par0150" class="elsevierStylePara elsevierViewall">This recently approved formulation combines 100<span class="elsevierStyleHsp" style=""></span>mg of grazoprevir &#40;HCV PI&#41; and 50<span class="elsevierStyleHsp" style=""></span>mg of elbasvir &#40;NS5A inhibitor&#41; in a single tablet&#44; administered once a day&#46;<a class="elsevierStyleCrossRef" href="#bib0325"><span class="elsevierStyleSup">29</span></a> The combination is approved for genotypes 1&#44; 4 and 6 and has shown its efficacy in patients coinfected with HIV and in advanced kidney disease stages IV and V&#44; including patients undergoing dialysis&#46; Its efficacy is above 90&#37;&#46; However&#44; the response rates are lower in genotype 1 when there are baseline NS5A resistance-associated polymorphisms at positions 28&#44; 30&#44; 31 or 93&#46;<a class="elsevierStyleCrossRef" href="#bib0325"><span class="elsevierStyleSup">29</span></a> In these cases or when a baseline resistance test is unavailable&#44; it is advisable to add ribavirin and extend the treatment to 16 weeks&#46;<a class="elsevierStyleCrossRef" href="#bib0325"><span class="elsevierStyleSup">29</span></a> If a patient has previously been treated with an HCV PI&#44; it is advisable to add ribavirin&#46;</p></span><span id="sec0080" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0100">Sofosbuvir&#47;ledipasvir &#40;Harvoni<span class="elsevierStyleSup">&#174;</span>&#44; Gilead&#41;</span><p id="par0155" class="elsevierStylePara elsevierViewall">This combination includes 400<span class="elsevierStyleHsp" style=""></span>mg of sofosbuvir and 90<span class="elsevierStyleHsp" style=""></span>mg of ledipasvir &#40;an NS5A inhibitor&#41; in a single tablet&#46; This was the first drug combination marketed for the treatment of HCV&#46; There is extensive experience with patients with genotypes 1 and 4&#44; in any stage of fibrosis&#44; including decompensated cirrhosis&#46;<a class="elsevierStyleCrossRef" href="#bib0330"><span class="elsevierStyleSup">30</span></a> The success rate of this combination in genotypes 1 and 4 is above 90&#37;&#46; The combination is less effective for genotype 3&#44; with which there is less experience&#46;</p><p id="par0160" class="elsevierStylePara elsevierViewall">For patients with genotype 1a for whom other regimens have failed&#44; it has been shown that the presence of mutations that confer high resistance to ledipasvir significantly decreases the treatment efficacy&#46; Therefore&#44; if these mutations are present or cannot be ruled out&#44; adding ribavirin to treatment regimen is recommended&#46;</p><p id="par0165" class="elsevierStylePara elsevierViewall">This combination has few drug interactions&#46;<a class="elsevierStyleCrossRef" href="#bib0260"><span class="elsevierStyleSup">16</span></a> Ledipasvir requires a low gastric pH for its absorption&#44; and proton pump inhibitors can decrease its efficacy&#46; When administered with tenofovir and an HIV PI&#44; the patient&#39;s renal function should be monitored&#46;<a class="elsevierStyleCrossRef" href="#bib0335"><span class="elsevierStyleSup">31</span></a> As with the use of sofosbuvir in isolation&#44; there is barely any experience when the glomerular filtration rate is lower than 30<span class="elsevierStyleHsp" style=""></span>mL&#47;min&#47;1&#46;73<span class="elsevierStyleHsp" style=""></span>m<span class="elsevierStyleSup">2</span>&#46;</p></span><span id="sec0085" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0105">Sofosbuvir&#47;velpatasvir &#40;Epclusa<span class="elsevierStyleSup">&#174;</span>&#44; Gilead&#41;</span><p id="par0170" class="elsevierStylePara elsevierViewall">This new combination of sofosbuvir and a second-generation NS5A inhibitor improves the activity against genotypes 2 and 3&#44; compared with ledipasvir&#46;<a class="elsevierStyleCrossRef" href="#bib0340"><span class="elsevierStyleSup">32</span></a> This combination is pangenotypic and is approved for genotypes 1 to 6&#46; The treatment duration is generally 12 weeks&#44; except for decompensated cirrhosis with genotype 3&#46; It is advisable to combine ribavirin only for decompensated cirrhosis and for pretreated patients or those with cirrhosis with the Y93H mutation and genotype 3 &#40;because the presence of this mutation in these patients is associated with reduced response&#41;&#46; The combinations main adverse effects are headache&#44; fatigue&#44; irritability and nausea&#46; The effects are usually mild and do not usually require withdrawal of the drug&#46;</p></span></span></span><span id="sec0090" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0110">Indications for treatment</span><p id="par0175" class="elsevierStylePara elsevierViewall">It is recommended that all patients with active HCV infection start treatment&#44;<a class="elsevierStyleCrossRef" href="#bib0230"><span class="elsevierStyleSup">10</span></a> whose objective is to reduce morbidity and mortality&#46; In decompensated cirrhosis&#44; the possibility of DAA treatment has changed these patients&#8217; natural history&#44; although the indication for transplantation cannot always be avoided&#46;<a class="elsevierStyleCrossRef" href="#bib0345"><span class="elsevierStyleSup">33</span></a></p><p id="par0180" class="elsevierStylePara elsevierViewall">Treatment in less advanced stages of fibrosis has been associated with a higher success rate&#44; a possibility of healing with shorter treatments and fewer adverse effects&#46; The effect of treatment on reducing transmission and eradicating the HCV infection is increasingly significant&#46;<a class="elsevierStyleCrossRef" href="#bib0350"><span class="elsevierStyleSup">34</span></a></p></span><span id="sec0095" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0115">Practical aspects of the treatment of chronic liver disease due to HCV</span><p id="par0185" class="elsevierStylePara elsevierViewall">Before starting HCV treatment&#44; we need the results of general laboratory tests&#44; the HCV genotype and subtype&#44; the viral load and the degree of hepatic fibrosis &#40;<a class="elsevierStyleCrossRef" href="#fig0010">Fig&#46; 2</a>&#41;&#46; We need to know the history of previous antiviral treatment failures and assess the presence of comorbidities&#46; It is important to determine the concomitant medication and review the potential interactions with the DAAs&#46; A simple&#44; fast and reliable way to do this is to use the University of Liverpool website &#40;hep-druginteractions&#46;org&#41;&#46;<a class="elsevierStyleCrossRef" href="#bib0260"><span class="elsevierStyleSup">16</span></a> It is also essential that patients be aware of the importance of good treatment adherence&#46;</p><elsevierMultimedia ident="fig0010"></elsevierMultimedia><p id="par0190" class="elsevierStylePara elsevierViewall">Except in highly specific circumstances that have already been mentioned&#44; the baseline resistances of the virus prior to the start of treatment have no impact on the SVR&#46;<a class="elsevierStyleCrossRef" href="#bib0355"><span class="elsevierStyleSup">35</span></a> Performing a baseline resistances study to guide the treatment regimen is therefore not recommended&#46;</p><p id="par0195" class="elsevierStylePara elsevierViewall">For patients with advanced fibrosis &#40;F3-F4&#41;&#44; an abdominal ultrasound should be available to rule out hepatocarcinoma&#46; Patients with cirrhosis and transient elastography readings higher than 20<span class="elsevierStyleHsp" style=""></span>kPa should also undergo upper endoscopy for the screening of esophageal varices&#46;<a class="elsevierStyleCrossRef" href="#bib0360"><span class="elsevierStyleSup">36</span></a> As with patients with advanced fibrosis and cirrhosis&#44; the SVR does not fully discount the possibility of developing an hepatocarcinoma&#46; Abdominal ultrasonography should be continued&#44; performing it every 6 months&#44; regardless of whether the HCV is cured&#46; During follow-up&#44; the only essential viral load is that measured 12 weeks after ending the treatment&#59; this reading will determine the SVR&#46;<a class="elsevierStyleCrossRef" href="#bib0235"><span class="elsevierStyleSup">11</span></a></p></span><span id="sec0100" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0120">Treatment regimens</span><p id="par0200" class="elsevierStylePara elsevierViewall">HCV treatment currently consists of the combination of at least 2 DAAs with different targets against the virus&#46;<a class="elsevierStyleCrossRef" href="#bib0235"><span class="elsevierStyleSup">11</span></a> Ribavirin is added in those situations in which it has been shown to increase the possibility of achieving an SVR&#46; Treatment duration varies from 8 to 24 weeks&#59; longer regimens are indicated for patients with decompensated cirrhosis&#46; The main characteristics of the employed combinations are summarized in <a class="elsevierStyleCrossRef" href="#fig0015">Fig&#46; 3</a>&#46; The treatment guidelines from the following associations should be reviewed in all cases&#58; the Spanish Association for the Study of the Liver&#44; the Spanish Society of Infectious Diseases and Clinical Microbiology&#44;<a class="elsevierStyleCrossRef" href="#bib0235"><span class="elsevierStyleSup">11</span></a> the European Association for the Study of the Liver<a class="elsevierStyleCrossRef" href="#bib0230"><span class="elsevierStyleSup">10</span></a> and the American Association for the Study of Liver Diseases&#46;<a class="elsevierStyleCrossRef" href="#bib0225"><span class="elsevierStyleSup">9</span></a></p><elsevierMultimedia ident="fig0015"></elsevierMultimedia><p id="par0205" class="elsevierStylePara elsevierViewall">The financial cost should also be considered when selecting the treatment regimen&#46; In Spain&#44; the price of the various drugs varies among the autonomous communities&#46; It is therefore important to consult the local guidelines that assess the cost-effectiveness of the drugs&#46;</p><p id="par0210" class="elsevierStylePara elsevierViewall">The recommended treatment regimens according to HCV genotype are listed in <a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>&#46; Combinations with simeprevir or daclatasvir are not included &#40;the latter except for genotypes 2 and 3&#41;&#44; because they offer no advantages over other more comfortable combinations with greater experience and lower cost&#46; In the European guidelines&#44; simeprevir appears as an alternative in genotype 4&#44; both in cirrhosis and in no cirrhosis&#46; Daclatasvir appears as an alternative for 12 or 24 weeks&#44; with or without ribavirin&#44; in all genotypes&#46;</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia></span><span id="sec0105" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0125">Conflict of interests</span><p id="par0215" class="elsevierStylePara elsevierViewall">C&#46; Quereda has participated in consulting activities for AbbVie&#44; Gilead and MSD laboratories&#44; as a speaker in AbbVie meetings and has occasionally attended congresses with funding from AbbVie&#44; Gilead and Jansen&#46;</p></span></span>"
    "textoCompletoSecciones" => array:1 [
      "secciones" => array:13 [
        0 => array:3 [
          "identificador" => "xres964031"
          "titulo" => "Abstract"
          "secciones" => array:1 [
            0 => array:1 [
              "identificador" => "abst0005"
            ]
          ]
        ]
        1 => array:2 [
          "identificador" => "xpalclavsec934100"
          "titulo" => "Keywords"
        ]
        2 => array:3 [
          "identificador" => "xres964032"
          "titulo" => "Resumen"
          "secciones" => array:1 [
            0 => array:1 [
              "identificador" => "abst0010"
            ]
          ]
        ]
        3 => array:2 [
          "identificador" => "xpalclavsec934101"
          "titulo" => "Palabras clave"
        ]
        4 => array:2 [
          "identificador" => "sec0005"
          "titulo" => "Background"
        ]
        5 => array:2 [
          "identificador" => "sec0010"
          "titulo" => "Replication cycle of the hepatitis C virus&#46; Therapeutic targets"
        ]
        6 => array:3 [
          "identificador" => "sec0015"
          "titulo" => "Direct-acting antivirals&#46; Classification according to their mechanism of action"
          "secciones" => array:3 [
            0 => array:2 [
              "identificador" => "sec0020"
              "titulo" => "NS3&#47;4A protease inhibitors"
            ]
            1 => array:2 [
              "identificador" => "sec0025"
              "titulo" => "NS5A inhibitors"
            ]
            2 => array:2 [
              "identificador" => "sec0030"
              "titulo" => "NS5B polymerase inhibitors"
            ]
          ]
        ]
        7 => array:3 [
          "identificador" => "sec0035"
          "titulo" => "Characteristics of the available drugs for HCV treatment"
          "secciones" => array:2 [
            0 => array:3 [
              "identificador" => "sec0040"
              "titulo" => "Drugs without coformulation"
              "secciones" => array:4 [
                0 => array:2 [
                  "identificador" => "sec0045"
                  "titulo" => "Simeprevir &#40;Olysio&#44; Janssen&#41;"
                ]
                1 => array:2 [
                  "identificador" => "sec0050"
                  "titulo" => "Daclatasvir &#40;Daklinza&#44; BMS&#41;"
                ]
                2 => array:2 [
                  "identificador" => "sec0055"
                  "titulo" => "Sofosbuvir &#40;Sovaldi&#44; Gilead&#41;"
                ]
                3 => array:2 [
                  "identificador" => "sec0060"
                  "titulo" => "Ribavirin"
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "sec0065"
              "titulo" => "Coformulated drugs"
              "secciones" => array:4 [
                0 => array:2 [
                  "identificador" => "sec0070"
                  "titulo" => "Paritaprevir&#47;ritonavir&#47;ombitasvir &#40;Viekirax&#44; Abbvie&#41; with or without dasabuvir &#40;Exviera&#44; Abbvie&#41;"
                ]
                1 => array:2 [
                  "identificador" => "sec0075"
                  "titulo" => "Grazoprevir&#47;elbasvir &#40;Zepatier&#44; MSD&#41;"
                ]
                2 => array:2 [
                  "identificador" => "sec0080"
                  "titulo" => "Sofosbuvir&#47;ledipasvir &#40;Harvoni&#44; Gilead&#41;"
                ]
                3 => array:2 [
                  "identificador" => "sec0085"
                  "titulo" => "Sofosbuvir&#47;velpatasvir &#40;Epclusa&#44; Gilead&#41;"
                ]
              ]
            ]
          ]
        ]
        8 => array:2 [
          "identificador" => "sec0090"
          "titulo" => "Indications for treatment"
        ]
        9 => array:2 [
          "identificador" => "sec0095"
          "titulo" => "Practical aspects of the treatment of chronic liver disease due to HCV"
        ]
        10 => array:2 [
          "identificador" => "sec0100"
          "titulo" => "Treatment regimens"
        ]
        11 => array:2 [
          "identificador" => "sec0105"
          "titulo" => "Conflict of interests"
        ]
        12 => array:1 [
          "titulo" => "References"
        ]
      ]
    ]
    "pdfFichero" => "main.pdf"
    "tienePdf" => true
    "fechaRecibido" => "2017-01-30"
    "fechaAceptado" => "2017-07-10"
    "PalabrasClave" => array:2 [
      "en" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec934100"
          "palabras" => array:2 [
            0 => "Hepatitis C virus"
            1 => "Direct-acting antivirals"
          ]
        ]
      ]
      "es" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec934101"
          "palabras" => array:2 [
            0 => "Virus de la hepatitis C"
            1 => "Antivirales de acci&#243;n directa"
          ]
        ]
      ]
    ]
    "tieneResumen" => true
    "resumen" => array:2 [
      "en" => array:2 [
        "titulo" => "Abstract"
        "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Hepatitis C virus infection is a significant public health problem&#46; The introduction of direct-acting antiviral agents&#44; whose efficacy is greater than 90&#37; in all patient groups &#40;including those with cirrhosis&#41;&#44; has represented a highly relevant change compared with classical interferon-based therapies&#46; Tolerance for these antiviral agents is significantly better&#44; and the treatment duration is shorter&#46; This review updates the treatment of hepatitis C virus infection with the new direct-acting antiviral agents&#46;</p></span>"
      ]
      "es" => array:2 [
        "titulo" => "Resumen"
        "resumen" => "<span id="abst0010" class="elsevierStyleSection elsevierViewall"><p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">La infecci&#243;n por el virus de la hepatitis C constituye un problema importante de salud p&#250;blica&#46; La introducci&#243;n de los antivirales de acci&#243;n directa&#44; cuya eficacia es superior al 90&#37; en todos los grupos de pacientes&#44; incluidos los cirr&#243;ticos&#44; ha supuesto un cambio muy relevante respecto al tratamiento con las terapias cl&#225;sicas basadas en interfer&#243;n&#46; Adem&#225;s&#44; la tolerancia de estos antivirales es significativamente mejor&#44; y la duraci&#243;n del tratamiento m&#225;s corta&#46; Esta revisi&#243;n pretende actualizar el tratamiento de la infecci&#243;n por el virus hepatitis C con los nuevos antivirales de acci&#243;n directa&#46;</p></span>"
      ]
    ]
    "NotaPie" => array:1 [
      0 => array:2 [
        "etiqueta" => "&#9734;"
        "nota" => "<p class="elsevierStyleNotepara" id="npar0015">Please cite this article as&#58; Vivancos MJ&#44; Moreno A&#44; Quereda C&#46; Tratamiento del virus de la hepatitis C con antivirales de acci&#243;n directa&#58; Aspectos pr&#225;cticos y situaci&#243;n actual&#46; Rev Clin Esp&#46; 2018&#59;218&#58;29&#8211;37&#46;</p>"
      ]
    ]
    "multimedia" => array:4 [
      0 => array:7 [
        "identificador" => "fig0005"
        "etiqueta" => "Figure 1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr1.jpeg"
            "Alto" => 1528
            "Ancho" => 2353
            "Tamanyo" => 232489
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Replication cycle of hepatitis C virus and therapeutic targets&#46;</p>"
        ]
      ]
      1 => array:7 [
        "identificador" => "fig0010"
        "etiqueta" => "Figure 2"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr2.jpeg"
            "Alto" => 2058
            "Ancho" => 2489
            "Tamanyo" => 245623
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">Factors to consider when selecting the therapeutic regimen&#46;</p>"
        ]
      ]
      2 => array:7 [
        "identificador" => "fig0015"
        "etiqueta" => "Figure 3"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr3.jpeg"
            "Alto" => 2618
            "Ancho" => 2910
            "Tamanyo" => 652451
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">Characteristics of the various drug families for the hepatitis C virus&#46;</p>"
        ]
      ]
      3 => array:8 [
        "identificador" => "tbl0005"
        "etiqueta" => "Table 1"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at1"
            "detalle" => "Table "
            "rol" => "short"
          ]
        ]
        "tabla" => array:3 [
          "leyenda" => "<p id="spar0035" class="elsevierStyleSimplePara elsevierViewall">Abbreviations&#58; DAA&#44; direct-acting antivirals&#59; DCV&#44; daclatasvir&#59; DSV&#44; dasabuvir&#59; EBR&#44; elbasvir&#59; GZR&#44; grazoprevir&#59; HCV&#44; hepatitis C virus&#59; LDV&#44; ledipasvir&#59; OBV&#44; ombitasvir&#59; PI&#44; protease inhibitor&#59; PTV&#44; paritaprevir&#59; RBV&#44; ribavirin&#59; RTV&#44; ritonavir&#59; SOF&#44; sofosbuvir&#59; VEL&#44; velpatasvir&#59; VL&#44; baseline viral load of HCV&#59; w&#44; weeks of treatment&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Genotype&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Regimens&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Duration and special considerations&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="table-entry  " rowspan="4" align="left" valign="top">1a</td><td class="td" title="table-entry  " align="left" valign="top">SOF<span class="elsevierStyleHsp" style=""></span>&#43;<span class="elsevierStyleHsp" style=""></span>LDV&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Only 8<span class="elsevierStyleHsp" style=""></span>w&#58; for treatment-naive&#44; CV<span class="elsevierStyleHsp" style=""></span>&#8804;6<span class="elsevierStyleHsp" style=""></span>&#215;<span class="elsevierStyleHsp" style=""></span>10<span class="elsevierStyleSup">6</span><span class="elsevierStyleHsp" style=""></span>UI&#47;mL&#44; and no cirrhosis &#40;caution in F3&#41;<br>12<span class="elsevierStyleHsp" style=""></span>w without RBV&#58; naive with or without compensated cirrhosis&#59; pretreated patients<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">a</span></a> without compensated cirrhosis if there are no resistances in NS5A<br>12<span class="elsevierStyleHsp" style=""></span>w<span class="elsevierStyleHsp" style=""></span>&#43;<span class="elsevierStyleHsp" style=""></span>RBV&#58; for decompensated cirrhosis<br>For pretreated patients<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">a</span></a> with NS5A resistances or without being able to rule them out&#44; with or without cirrhosis<br>24<span class="elsevierStyleHsp" style=""></span>w&#58; for the previous case and contraindication for RBV<br>24<span class="elsevierStyleHsp" style=""></span>w<span class="elsevierStyleHsp" style=""></span>&#43;<span class="elsevierStyleHsp" style=""></span>RBV&#58; for patients with liver transplants and decompensated cirrhosis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">PTV&#47;RTV<span class="elsevierStyleHsp" style=""></span>&#43;<span class="elsevierStyleHsp" style=""></span>OBV<span class="elsevierStyleHsp" style=""></span>&#43;<span class="elsevierStyleHsp" style=""></span>DSV<span class="elsevierStyleHsp" style=""></span>&#43;<span class="elsevierStyleHsp" style=""></span>RBV&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">12<span class="elsevierStyleHsp" style=""></span>w&#58; for no cirrhosis&#59; 24<span class="elsevierStyleHsp" style=""></span>w&#58; for compensated cirrhosis<br>Should not be used for decompensated cirrhosis or for previous failures with PI&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">GZR<span class="elsevierStyleHsp" style=""></span>&#43;<span class="elsevierStyleHsp" style=""></span>EBR&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">12<span class="elsevierStyleHsp" style=""></span>w without RBV&#58; if there are no resistances to EBV or if CV &#8804;800&#44;000<span class="elsevierStyleHsp" style=""></span>IU&#47;mL<br>16<span class="elsevierStyleHsp" style=""></span>w<span class="elsevierStyleHsp" style=""></span>&#43;<span class="elsevierStyleHsp" style=""></span>RBV&#58; if there is resistance to EBV &#40;or test is not available&#41; and&#47;or CV &#62;800&#44;000<span class="elsevierStyleHsp" style=""></span>IU&#47;mL<br>Should not be used for decompensated cirrhosis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">SOF<span class="elsevierStyleHsp" style=""></span>&#43;<span class="elsevierStyleHsp" style=""></span>VEL&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">12<span class="elsevierStyleHsp" style=""></span>w<br>12<span class="elsevierStyleHsp" style=""></span>w<span class="elsevierStyleHsp" style=""></span>&#43;<span class="elsevierStyleHsp" style=""></span>RBV&#58; for decompensated cirrhosis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="3" align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="table-entry  " rowspan="4" align="left" valign="top">1b</td><td class="td" title="table-entry  " align="left" valign="top">SOF<span class="elsevierStyleHsp" style=""></span>&#43;<span class="elsevierStyleHsp" style=""></span>LDV&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Only 8<span class="elsevierStyleHsp" style=""></span>w&#58; for treatment-naive&#44; CV<span class="elsevierStyleHsp" style=""></span>&#8804;6<span class="elsevierStyleHsp" style=""></span>&#215;<span class="elsevierStyleHsp" style=""></span>10<span class="elsevierStyleSup">6</span><span class="elsevierStyleHsp" style=""></span>UI&#47;mL&#44; and no cirrhosis &#40;caution in F3&#41;<br>12<span class="elsevierStyleHsp" style=""></span>w without RBV&#58; naive with CV<span class="elsevierStyleHsp" style=""></span>&#62;6<span class="elsevierStyleHsp" style=""></span>&#215;<span class="elsevierStyleHsp" style=""></span>10<span class="elsevierStyleSup">6</span><span class="elsevierStyleHsp" style=""></span>IU&#47;mL or cirrhosis&#59; pretreated patients<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">a</span></a> without cirrhosis<br>12<span class="elsevierStyleHsp" style=""></span>w<span class="elsevierStyleHsp" style=""></span>&#43;<span class="elsevierStyleHsp" style=""></span>RBV&#58; in pretreated<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">a</span></a> compensated cirrhosis<a class="elsevierStyleCrossRef" href="#tblfn0010"><span class="elsevierStyleSup">b</span></a>&#59; in decompensated cirrhosis<br>24<span class="elsevierStyleHsp" style=""></span>w<span class="elsevierStyleHsp" style=""></span>&#43;<span class="elsevierStyleHsp" style=""></span>RBV&#58; for patients with liver transplants and decompensated cirrhosis<br>24<span class="elsevierStyleHsp" style=""></span>w without RBV&#58; if there is an indication for RBV and with contraindication for the same&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">PTV&#47;RTV<span class="elsevierStyleHsp" style=""></span>&#43;<span class="elsevierStyleHsp" style=""></span>OBV<span class="elsevierStyleHsp" style=""></span>&#43;<span class="elsevierStyleHsp" style=""></span>DSV&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">12<span class="elsevierStyleHsp" style=""></span>w without RBV<br>8<span class="elsevierStyleHsp" style=""></span>w without RBV&#58; for treatment-naive and no cirrhosis &#40;caution in F3&#41;<br>Should not be used for decompensated cirrhosis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">GZR<span class="elsevierStyleHsp" style=""></span>&#43;<span class="elsevierStyleHsp" style=""></span>EBR&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">12<span class="elsevierStyleHsp" style=""></span>w<br>Should not be used for decompensated cirrhosis<br>Add RBV if previous failure to PI&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">SOF<span class="elsevierStyleHsp" style=""></span>&#43;<span class="elsevierStyleHsp" style=""></span>VEL&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">12<span class="elsevierStyleHsp" style=""></span>w&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="3" align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="table-entry  " rowspan="3" align="left" valign="top">2</td><td class="td" title="table-entry  " align="left" valign="top">SOF<span class="elsevierStyleHsp" style=""></span>&#43;<span class="elsevierStyleHsp" style=""></span>RBV&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">12<span class="elsevierStyleHsp" style=""></span>w&#59; 24 s&#58; for cirrhosis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">SOF<span class="elsevierStyleHsp" style=""></span>&#43;<span class="elsevierStyleHsp" style=""></span>DCV&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">12<span class="elsevierStyleHsp" style=""></span>w&#58; scarce experience with this regimen&#59; add RBV&#58; for decompensated cirrhosis<br>16&#8211;24<span class="elsevierStyleHsp" style=""></span>w&#58; for compensated cirrhosis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">SOF<span class="elsevierStyleHsp" style=""></span>&#43;<span class="elsevierStyleHsp" style=""></span>VEL&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">12<span class="elsevierStyleHsp" style=""></span>w&#59; add RBV&#58; for decompensated cirrhosis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="3" align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="table-entry  " rowspan="2" align="left" valign="top">3</td><td class="td" title="table-entry  " align="left" valign="top">SOF<span class="elsevierStyleHsp" style=""></span>&#43;<span class="elsevierStyleHsp" style=""></span>DCV&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">12<span class="elsevierStyleHsp" style=""></span>w&#58; treatment-naive without cirrhosis&#59; for pretreated<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">a</span></a> only if no Y93H mutation<br>12<span class="elsevierStyleHsp" style=""></span>w with RBV&#58; for pretreated without cirrhosis and with the Y93H resistance mutation or with no available resistance test<br>24<span class="elsevierStyleHsp" style=""></span>w with RBV&#58; for compensated or decompensated cirrhosis<br>24<span class="elsevierStyleHsp" style=""></span>w&#58; if RBV is recommended and contraindication to receive it&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">SOF<span class="elsevierStyleHsp" style=""></span>&#43;<span class="elsevierStyleHsp" style=""></span>VEL&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">12<span class="elsevierStyleHsp" style=""></span>w&#58; for treatment-naive without cirrhosis&#59; for pretreated<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">a</span></a> or cirrhosis&#44; only if there is no Y93H mutation<br>12<span class="elsevierStyleHsp" style=""></span>w with RBV&#58; for pretreated patients<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">a</span></a> or those with cirrhosis and with the Y93H resistance mutation or with no available resistance test<br>24<span class="elsevierStyleHsp" style=""></span>w with RBV&#58; for compensated cirrhosis<br>24<span class="elsevierStyleHsp" style=""></span>w&#58; if RBV is recommended and contraindication to receive it&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="3" align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="table-entry  " rowspan="4" align="left" valign="top">4</td><td class="td" title="table-entry  " align="left" valign="top">SOF<span class="elsevierStyleHsp" style=""></span>&#43;<span class="elsevierStyleHsp" style=""></span>LDV&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">12<span class="elsevierStyleHsp" style=""></span>w&#58; treatment-naive<br>12<span class="elsevierStyleHsp" style=""></span>w<span class="elsevierStyleHsp" style=""></span>&#43;<span class="elsevierStyleHsp" style=""></span>RBV&#58; for pretreated patients<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">a</span></a> and for decompensated cirrhosis<br>24<span class="elsevierStyleHsp" style=""></span>w&#58; if RBV is recommended and contraindication to receive it&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">PTV&#47;RTV<span class="elsevierStyleHsp" style=""></span>&#43;<span class="elsevierStyleHsp" style=""></span>OBV<span class="elsevierStyleHsp" style=""></span>&#43;<span class="elsevierStyleHsp" style=""></span>RBV&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">12<span class="elsevierStyleHsp" style=""></span>s &#43;&#47;&#8722; RBV &#40;if there are problems with RBV&#44; the regimen without RBV can be administered&#41;<br>Should not be used for decompensated cirrhosis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">GZR<span class="elsevierStyleHsp" style=""></span>&#43;<span class="elsevierStyleHsp" style=""></span>EBR&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">12<span class="elsevierStyleHsp" style=""></span>w<br>16<span class="elsevierStyleHsp" style=""></span>s with RBV&#58; assess this regimen in pretreated patients<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">a</span></a> and CV &#60;800&#44;000<span class="elsevierStyleHsp" style=""></span>IU&#47;mL<br>Should not be used for decompensated cirrhosis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">SOF<span class="elsevierStyleHsp" style=""></span>&#43;<span class="elsevierStyleHsp" style=""></span>VEL&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">12<span class="elsevierStyleHsp" style=""></span>w<br>12<span class="elsevierStyleHsp" style=""></span>w with RBV&#58; for decompensated cirrhosis<br>24<span class="elsevierStyleHsp" style=""></span>s&#58; in decompensated cirrhosis and contraindication for RBV&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab1633349.png"
              ]
            ]
          ]
          "notaPie" => array:2 [
            0 => array:3 [
              "identificador" => "tblfn0005"
              "etiqueta" => "a"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Pretreated refers to a previous failure with regimens with interferon and RBV&#43;&#47;&#8722; first-generation PI&#46; For failures with DAA&#44; consult an expert&#46;</p>"
            ]
            1 => array:3 [
              "identificador" => "tblfn0010"
              "etiqueta" => "b"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0010">The European guidelines recommend 12 weeks without RBV&#44; while the American guidelines recommend 12 weeks with RBV&#46;</p>"
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">Treatment regimens for chronic hepatitis C virus infection according to genotype&#46;</p>"
        ]
      ]
    ]
    "bibliografia" => array:2 [
      "titulo" => "References"
      "seccion" => array:1 [
        0 => array:2 [
          "identificador" => "bibs0015"
          "bibliografiaReferencia" => array:36 [
            0 => array:3 [
              "identificador" => "bib0185"
              "etiqueta" => "1"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Global epidemiology of hepatitis C virus infection&#58; new estimates of age-specific antibody to HCV seroprevalence"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "K&#46; Mohd Hanafiah"
                            1 => "J&#46; Groeger"
                            2 => "A&#46;D&#46; Flaxman"
                            3 => "S&#46;T&#46; Wiersma"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1002/hep.26141"
                      "Revista" => array:6 [
                        "tituloSerie" => "Hepatology"
                        "fecha" => "2013"
                        "volumen" => "57"
                        "paginaInicial" => "1333"
                        "paginaFinal" => "1342"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23172780"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "bib0190"
              "etiqueta" => "2"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Global distribution and prevalence of hepatitis C virus genotypes"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "J&#46;P&#46; Messina"
                            1 => "I&#46; Humphreys"
                            2 => "A&#46; Flaxman"
                            3 => "A&#46; Brown"
                            4 => "G&#46;S&#46; Cooke"
                            5 => "O&#46;G&#46; Pybus"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Hematology"
                        "fecha" => "2015"
                        "volumen" => "61"
                        "paginaInicial" => "77"
                        "paginaFinal" => "87"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            2 => array:3 [
              "identificador" => "bib0195"
              "etiqueta" => "3"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Aging of hepatitis C virus &#40;HCV&#41;-infected persons in the United States&#58; a multiple cohort model of HCV prevalence and disease progression"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "G&#46;L&#46; Davis"
                            1 => "M&#46;J&#46; Alter"
                            2 => "H&#46; El-Serag"
                            3 => "T&#46; Poynard"
                            4 => "L&#46;W&#46; Jennings"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1053/j.gastro.2009.09.067"
                      "Revista" => array:6 [
                        "tituloSerie" => "Gastroenterology"
                        "fecha" => "2010"
                        "volumen" => "138"
                        "paginaInicial" => "513"
                        "paginaFinal" => "514"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19861128"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            3 => array:3 [
              "identificador" => "bib0200"
              "etiqueta" => "4"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Epidemiology and natural history of HCV infection"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "B&#46; Hajarizadeh"
                            1 => "J&#46; Grebely"
                            2 => "G&#46;J&#46; Dore"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Nat Rev Gastroenterol Hepat"
                        "fecha" => "2013"
                        "volumen" => "10"
                        "paginaInicial" => "553"
                        "paginaFinal" => "562"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            4 => array:3 [
              "identificador" => "bib0205"
              "etiqueta" => "5"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010&#58; a systematic analysis for the Global Burden of Disease Study 2010"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "R&#46; Lozano"
                            1 => "M&#46; Naghavi"
                            2 => "K&#46; Foreman"
                            3 => "S&#46; Lim"
                            4 => "K&#46; Shibuya"
                            5 => "V&#46; Aboyans"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/S0140-6736(12)61728-0"
                      "Revista" => array:6 [
                        "tituloSerie" => "Lancet"
                        "fecha" => "2012"
                        "volumen" => "380"
                        "paginaInicial" => "2095"
                        "paginaFinal" => "2128"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23245604"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            5 => array:3 [
              "identificador" => "bib0210"
              "etiqueta" => "6"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "S&#46; Maylin"
                            1 => "M&#46; Martinot-Peignoux"
                            2 => "R&#46; Moucari"
                            3 => "N&#46; Boyer"
                            4 => "M&#46;P&#46; Ripault"
                            5 => "D&#46; Cazals-Hatem"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1053/j.gastro.2008.05.044"
                      "Revista" => array:6 [
                        "tituloSerie" => "Gastroenterology"
                        "fecha" => "2008"
                        "volumen" => "135"
                        "paginaInicial" => "821"
                        "paginaFinal" => "829"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18593587"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            6 => array:3 [
              "identificador" => "bib0215"
              "etiqueta" => "7"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Improvement of liver function parameters in advanced HCV-associated liver cirrhosis by IFN-free antiviral therapies"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "K&#46; Deterding"
                            1 => "C&#46; Honer Zu Siederdissen"
                            2 => "K&#46; Port"
                            3 => "P&#46; Solbach"
                            4 => "L&#46; Sollik"
                            5 => "J&#46; Kirschner"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/apt.13343"
                      "Revista" => array:6 [
                        "tituloSerie" => "Aliment Pharmacol Ther"
                        "fecha" => "2015"
                        "volumen" => "42"
                        "paginaInicial" => "889"
                        "paginaFinal" => "901"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26250762"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            7 => array:3 [
              "identificador" => "bib0220"
              "etiqueta" => "8"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "A brief history of the treatment of viral hepatitis C"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "D&#46;B&#46; Strader"
                            1 => "L&#46;B&#46; Seeff"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Clin Liver Dis"
                        "fecha" => "2012"
                        "volumen" => "1"
                        "paginaInicial" => "6"
                        "paginaFinal" => "11"
                        "itemHostRev" => array:3 [
                          "pii" => "S0140673608600744"
                          "estado" => "S300"
                          "issn" => "01406736"
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            8 => array:3 [
              "identificador" => "bib0225"
              "etiqueta" => "9"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "Recommendations for testing&#44; managing&#44; and treating hepatitis C&#46; American Association for the Study of Liver Diseases and the Infectious Diseases Society of America&#46; Available from&#58; <a href="http://www.hcvguidelines.org/">http&#58;&#47;&#47;www&#46;hcvguidelines&#46;org</a> &#91;accessed 11&#46;12&#46;16&#93;&#46;"
                ]
              ]
            ]
            9 => array:3 [
              "identificador" => "bib0230"
              "etiqueta" => "10"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "EASL recommendations on treatment of hepatitis C 2016"
                      "autores" => array:1 [
                        0 => array:2 [
                          "colaboracion" => "European Association for the Study of the Liver"
                          "etal" => false
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jhep.2016.09.001"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Hepatol"
                        "fecha" => "2017"
                        "volumen" => "66"
                        "paginaInicial" => "153"
                        "paginaFinal" => "194"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27667367"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            10 => array:3 [
              "identificador" => "bib0235"
              "etiqueta" => "11"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "Gu&#237;as AEEH&#47;SEIMC de manejo de la hepatitis C&#46; Available from&#58; <a href="http://aeeh.es/wp-content/uploads/2017/06/consenso.pdf">http&#58;&#47;&#47;aeeh&#46;es&#47;wp-content&#47;uploads&#47;2017&#47;06&#47;consenso&#46;pdf</a> &#91;accessed July 2017&#93;&#46;"
                ]
              ]
            ]
            11 => array:3 [
              "identificador" => "bib0240"
              "etiqueta" => "12"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Interaction of hepatitis C virus nonstructural protein 5A with core protein is critical for the production of infectious virus particles"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "T&#46; Masaki"
                            1 => "R&#46; Suzuki"
                            2 => "K&#46; Murakami"
                            3 => "H&#46; Aizaki"
                            4 => "K&#46; Ishii"
                            5 => "A&#46; Murayama"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1128/JVI.00826-08"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Virol"
                        "fecha" => "2008"
                        "volumen" => "82"
                        "paginaInicial" => "7964"
                        "paginaFinal" => "7976"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18524832"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            12 => array:3 [
              "identificador" => "bib0245"
              "etiqueta" => "13"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Biolog&#237;a molecular aplicada del virus de la hepatitis C"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "G&#46; Koutsoudakis"
                            1 => "X&#46; Forns"
                            2 => "S&#46; P&#233;rez del Pulgar"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.gastrohep.2012.11.005"
                      "Revista" => array:6 [
                        "tituloSerie" => "Gastroenterol Hepatol"
                        "fecha" => "2013"
                        "volumen" => "36"
                        "paginaInicial" => "280"
                        "paginaFinal" => "293"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23490024"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            13 => array:3 [
              "identificador" => "bib0250"
              "etiqueta" => "14"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Boceprevir for untreated chronic HCV genotype 1 infection"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "F&#46; Poordad"
                            1 => "J&#46; McCone Jr&#46;"
                            2 => "B&#46;R&#46; Bacon"
                            3 => "S&#46; Bruno"
                            4 => "M&#46;P&#46; Manns"
                            5 => "M&#46;S&#46; Sulkowski"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1056/NEJMoa1010494"
                      "Revista" => array:6 [
                        "tituloSerie" => "N Engl J Med"
                        "fecha" => "2011"
                        "volumen" => "364"
                        "paginaInicial" => "1195"
                        "paginaFinal" => "1206"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21449783"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            14 => array:3 [
              "identificador" => "bib0255"
              "etiqueta" => "15"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Telaprevir for previously untreated chronic hepatitis C virus infection"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "I&#46;M&#46; Jacobson"
                            1 => "J&#46;G&#46; McHutchison"
                            2 => "G&#46; Dusheiko"
                            3 => "A&#46;M&#46; di Bisceglie"
                            4 => "K&#46;R&#46; Reddy"
                            5 => "N&#46;H&#46; Bzowej"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "N Engl J Med"
                        "fecha" => "2011"
                        "volumen" => "23"
                        "paginaInicial" => "2405"
                        "paginaFinal" => "2416"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            15 => array:3 [
              "identificador" => "bib0260"
              "etiqueta" => "16"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "HEP Drug Interaction Checker&#44; Liverpool University&#46; Available from&#58; <a href="http://hep-druginteractions.org/">http&#58;&#47;&#47;hep-druginteractions&#46;org&#47;</a> &#91;accessed December 2017&#93;&#46;"
                ]
              ]
            ]
            16 => array:3 [
              "identificador" => "bib0265"
              "etiqueta" => "17"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "Zeuzem S&#44; Feld J&#44; Wang S&#44; Wang S&#44; Bourli&#232;re M&#44; Wedemeyer H&#44; et al&#46; ENDURANCE-1&#58; a phase 3 evaluation of the efficacy and safety of 8- versus 12-week treatment with glecaprevir&#47;pibrentasvir &#40;formerly ABT-493&#47;ABT-530&#41; in HCV genotype 1 infected patients with or without HIV-1 co-infection and without cirrhosis&#46; Presented at AASLD&#44; November 11&#8211;15&#44; 2016&#44; Boston&#44; MA&#46;"
                ]
              ]
            ]
            17 => array:3 [
              "identificador" => "bib0270"
              "etiqueta" => "18"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "Zeuzem S&#44; Flamm SL&#44; Tong M&#44; Vierling JM&#44; Pianko S&#44; Buggisch P&#44; et al&#46; A randomized&#44; controlled&#44; phase 3 trial of sofosbuvir&#47;velpatasvir&#47;voxilaprevir or sofosbuvir&#47;velpatasvir for 12 weeks in direct-acting antiviral-experienced patients with genotype 1-6 HCV infection&#58; the POLARIS-4 Study&#46; Presented at AASLD&#44; November 11&#8211;15&#44; 2016&#44; Boston&#44; MA&#46;"
                ]
              ]
            ]
            18 => array:3 [
              "identificador" => "bib0275"
              "etiqueta" => "19"
              "referencia" => array:1 [
                0 => array:3 [
                  "comentario" => "PMID&#58; <span class="elsevierStyleInterRef" id="intr0025" href="pmid:27353271">27353271</span>"
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Clinical resistance to velpatasvir &#40;GS-5816&#41;&#44; a novel pan-genotypic inhibitor of the hepatitis C virus NS5A protein"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "E&#46;J&#46; Lawitz"
                            1 => "H&#46; Dvory-Sobol"
                            2 => "B&#46;P&#46; Doehle"
                            3 => "A&#46;S&#46; Worth"
                            4 => "J&#46; McNally"
                            5 => "D&#46;M&#46; Brainard"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1128/AAC.00763-16"
                      "Revista" => array:6 [
                        "tituloSerie" => "Antimicrob Agents Chemother"
                        "fecha" => "2016"
                        "volumen" => "60"
                        "paginaInicial" => "5368"
                        "paginaFinal" => "5378"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27353271"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            19 => array:3 [
              "identificador" => "bib0280"
              "etiqueta" => "20"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Simeprevir with pegylated interferon alpha 2a or 2b plus ribavirin in treatment-na&#239;ve patients with chronic hepatitis C virus genotype 1 infection &#40;QUEST-2&#41;&#58; a randomised&#44; double-blind&#44; placebo-controlled phase 3 trial"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "M&#46; Manns"
                            1 => "P&#46; Marcellin"
                            2 => "F&#46; Poordad"
                            3 => "E&#46;S&#46; de Araujo"
                            4 => "M&#46; Buti"
                            5 => "Y&#46; Horsmans"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Lancet"
                        "fecha" => "2014"
                        "volumen" => "2"
                        "paginaInicial" => "414"
                        "paginaFinal" => "426"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/2569600"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            20 => array:3 [
              "identificador" => "bib0285"
              "etiqueta" => "21"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Simeprevir and sofosbuvir for treatment of chronic hepatitis C infection"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "L&#46;M&#46; Childs-Kean"
                            1 => "E&#46;O&#46; Hand"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.clinthera.2014.12.012"
                      "Revista" => array:6 [
                        "tituloSerie" => "Clin Ther"
                        "fecha" => "2015"
                        "volumen" => "37"
                        "paginaInicial" => "243"
                        "paginaFinal" => "267"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25601269"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            21 => array:3 [
              "identificador" => "bib0290"
              "etiqueta" => "22"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Daclatasvir plus simeprevir with or without ribavirin for the treatment of chronic hepatitis C virus genotype 1 infection"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "S&#46; Zeuzem"
                            1 => "C&#46; H&#233;zode"
                            2 => "J&#46;P&#46; Bronowicki"
                            3 => "V&#46; Loustaud-Ratti"
                            4 => "F&#46; Gea"
                            5 => "M&#46; Buti"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jhep.2015.09.024"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Hepatol"
                        "fecha" => "2016"
                        "volumen" => "64"
                        "paginaInicial" => "292"
                        "paginaFinal" => "300"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26453968"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            22 => array:3 [
              "identificador" => "bib0295"
              "etiqueta" => "23"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Simeprevir plus sofosbuvir&#44; with or without ribavirin&#44; to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-na&#239;ve patients&#58; the COSMOS randomised study"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "E&#46; Lawitz"
                            1 => "M&#46;S&#46; Sulkowski"
                            2 => "R&#46; Ghalib"
                            3 => "M&#46; Rodriguez-Torres"
                            4 => "Z&#46;M&#46; Younossi"
                            5 => "A&#46; Corregidor"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Lancet"
                        "fecha" => "2014"
                        "volumen" => "15"
                        "paginaInicial" => "1756"
                        "paginaFinal" => "1765"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            23 => array:3 [
              "identificador" => "bib0300"
              "etiqueta" => "24"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Update on hepatitis C virus resistance to direct-acting antiviral agents"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [
                            0 => "E&#46; Poveda"
                            1 => "D&#46;L&#46; Wyles"
                            2 => "A&#46; Mena"
                            3 => "J&#46;D&#46; Pedreira"
                            4 => "A&#46; Castro-Iglesias"
                            5 => "E&#46; Cachay"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.antiviral.2014.05.015"
                      "Revista" => array:6 [
                        "tituloSerie" => "Antiviral Res"
                        "fecha" => "2014"
                        "volumen" => "108"
                        "paginaInicial" => "181"
                        "paginaFinal" => "191"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24911972"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            24 => array:3 [
              "identificador" => "bib0305"
              "etiqueta" => "25"
              "referencia" => array:1 [
                0 => array:3 [
                  "comentario" => "Available from&#58; <span class="elsevierStyleInterRef" id="intr0030" href="https://www.olysio.com/shared/product/olysio/prescribing-information.pdf">https&#58;&#47;&#47;www&#46;olysio&#46;com&#47;shared&#47;product&#47;olysio&#47;prescribing-information&#46;pdf</span> &#91;accessed 11&#46;12&#46;16&#93;"
                  "contribucion" => array:1 [
                    0 => array:1 [
                      "titulo" => "Olysio &#40;simeprevir&#41; package insert"
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Libro" => array:3 [
                        "fecha" => "May 2016"
                        "editorial" => "Janssen Therapeutics"
                        "editorialLocalizacion" => "Titusville&#44; NJ"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            25 => array:3 [
              "identificador" => "bib0310"
              "etiqueta" => "26"
              "referencia" => array:1 [
                0 => array:3 [
                  "comentario" => "Available from&#58; <span class="elsevierStyleInterRef" id="intr0035" href="http://packageinserts.bms.com/pi/pi_daklinza.pdf">http&#58;&#47;&#47;packageinserts&#46;bms&#46;com&#47;pi&#47;pi&#95;daklinza&#46;pdf</span> &#91;accessed 11&#46;12&#46;16&#93;"
                  "contribucion" => array:1 [
                    0 => array:1 [
                      "titulo" => "Daklinza &#40;daclatasvir&#41; prescribing information"
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Libro" => array:3 [
                        "fecha" => "February 2016"
                        "editorial" => "Bristol-Myers Squibb Co&#46;"
                        "editorialLocalizacion" => "Princeton&#44; NJ"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            26 => array:3 [
              "identificador" => "bib0315"
              "etiqueta" => "27"
              "referencia" => array:1 [
                0 => array:3 [
                  "comentario" => "Available from&#58; <span class="elsevierStyleInterRef" id="intr0040" href="http://www.gilead.ca/pdf/ca/sovaldi_pm_english.pdf">http&#58;&#47;&#47;www&#46;gilead&#46;ca&#47;pdf&#47;ca&#47;sovaldi&#95;pm&#95;english&#46;pdf</span> &#91;accessed 11&#46;12&#46;16&#93;"
                  "contribucion" => array:1 [
                    0 => array:1 [
                      "titulo" => "Sovaldi &#40;sofosbuvir&#41; product monograph"
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Libro" => array:3 [
                        "fecha" => "July 2015"
                        "editorial" => "Gilead Sciences Canada&#44; Inc&#46;"
                        "editorialLocalizacion" => "Mississauga&#44; Ontario&#44; Canada"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            27 => array:3 [
              "identificador" => "bib0320"
              "etiqueta" => "28"
              "referencia" => array:1 [
                0 => array:3 [
                  "comentario" => "Available from&#58; <span class="elsevierStyleInterRef" id="intr0045" href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206619lbl.pdf">https&#58;&#47;&#47;www&#46;accessdata&#46;fda&#46;gov&#47;drugsatfda&#95;docs&#47;label&#47;2014&#47;206619lbl&#46;pdf</span> &#91;accessed 11&#46;12&#46;16&#93;"
                  "contribucion" => array:1 [
                    0 => array:1 [
                      "titulo" => "Viekira Pak &#40;ombitasvir&#44; paritaprevir&#44; ritonavir&#44; dasabuvir&#41; prescribing information"
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Libro" => array:3 [
                        "fecha" => "June 2016"
                        "editorial" => "AbbVie Inc&#46;"
                        "editorialLocalizacion" => "North Chicago&#44; IL"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            28 => array:3 [
              "identificador" => "bib0325"
              "etiqueta" => "29"
              "referencia" => array:1 [
                0 => array:3 [
                  "comentario" => "Available from&#58; <span class="elsevierStyleInterRef" id="intr0050" href="https://www.merck.com/product/usa/pi_circulars/z/zepatier/zepatier_pi.pdf">https&#58;&#47;&#47;www&#46;merck&#46;com&#47;product&#47;usa&#47;pi&#95;circulars&#47;z&#47;zepatier&#47;zepatier&#95;pi&#46;pdf</span> &#91;accessed 11&#46;12&#46;16&#93;"
                  "contribucion" => array:1 [
                    0 => array:1 [
                      "titulo" => "Zepatier &#40;elbasvir and grazoprevir&#41; prescribing information"
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Libro" => array:3 [
                        "fecha" => "January 2016"
                        "editorial" => "Merck Sharp &#38; Dohme Corp&#46;"
                        "editorialLocalizacion" => "Whitehouse Station&#44; NJ"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            29 => array:3 [
              "identificador" => "bib0330"
              "etiqueta" => "30"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease"
                      "autores" => array:1 [
                        0 => array:3 [
                          "colaboracion" => "SOLAR-1 investigators"
                          "etal" => true
                          "autores" => array:6 [
                            0 => "M&#46; Charlton"
                            1 => "G&#46;T&#46; Everson"
                            2 => "S&#46;L&#46; Flamm"
                            3 => "P&#46; Kumar"
                            4 => "C&#46; Landis"
                            5 => "R&#46;S&#46; Brown Jr&#46;"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1053/j.gastro.2015.05.010"
                      "Revista" => array:6 [
                        "tituloSerie" => "Gastroenterology"
                        "fecha" => "2015"
                        "volumen" => "149"
                        "paginaInicial" => "649"
                        "paginaFinal" => "659"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25985734"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            30 => array:3 [
              "identificador" => "bib0335"
              "etiqueta" => "31"
              "referencia" => array:1 [
                0 => array:3 [
                  "comentario" => "Available from&#58; <span class="elsevierStyleInterRef" id="intr0055" href="https://www.gilead.com/~/media/Files/pdfs/medicines/liver-disease/harvoni/harvoni_pi.pdf">https&#58;&#47;&#47;www&#46;gilead&#46;com&#47;&#8764;&#47;media&#47;Files&#47;pdfs&#47;medicines&#47;liver-disease&#47;harvoni&#47;harvoni&#95;pi&#46;pdf</span> &#91;accessed 11&#46;12&#46;16&#93;"
                  "contribucion" => array:1 [
                    0 => array:1 [
                      "titulo" => "Harvoni &#40;ledipasvir&#47;sofosbuvir&#41; prescribing information"
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Libro" => array:3 [
                        "fecha" => "June 2016"
                        "editorial" => "Gilead Sciences Inc&#46;"
                        "editorialLocalizacion" => "Foster City&#44; CA"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            31 => array:3 [
              "identificador" => "bib0340"
              "etiqueta" => "32"
              "referencia" => array:1 [
                0 => array:3 [
                  "comentario" => "Available from&#58; <span class="elsevierStyleInterRef" id="intr0060" href="https://www.gilead.com/~/media/files/pdfs/medicines/liver-disease/epclusa/epclusa_pi.pdf">https&#58;&#47;&#47;www&#46;gilead&#46;com&#47;&#8764;&#47;media&#47;files&#47;pdfs&#47;medicines&#47;liver-disease&#47;epclusa&#47;epclusa&#95;pi&#46;pdf</span> &#91;accessed 11&#46;12&#46;16&#93;"
                  "contribucion" => array:1 [
                    0 => array:1 [
                      "titulo" => "Epclusa &#40;sofosbuvir and velpatasvir&#41; prescribing information"
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Libro" => array:3 [
                        "fecha" => "June 2016"
                        "editorial" => "Gilead Sciences Inc&#46;"
                        "editorialLocalizacion" => "Foster City&#44; CA"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            32 => array:3 [
              "identificador" => "bib0345"
              "etiqueta" => "33"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease&#58; analysis of data from the Hepa-C registry"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "C&#46; Fern&#225;ndez-Carrillo"
                            1 => "S&#46; Lens"
                            2 => "E&#46; Llop"
                            3 => "J&#46;M&#46; Pascasio"
                            4 => "J&#46; Crespo"
                            5 => "J&#46; Arenas"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1002/hep.29097"
                      "Revista" => array:6 [
                        "tituloSerie" => "Hepatology"
                        "fecha" => "2017"
                        "volumen" => "65"
                        "paginaInicial" => "1810"
                        "paginaFinal" => "1822"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28170112"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            33 => array:3 [
              "identificador" => "bib0350"
              "etiqueta" => "34"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Achieving sustained virological response&#58; what&#39;s the impact on further hepatitis C virus-related disease&#63;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:1 [
                            0 => "A&#46;J&#46; Van der Meer"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1586/17474124.2015.1001366"
                      "Revista" => array:6 [
                        "tituloSerie" => "Expert Rev Gastroenterol Hepatol"
                        "fecha" => "2015"
                        "volumen" => "9"
                        "paginaInicial" => "559"
                        "paginaFinal" => "566"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25579804"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            34 => array:3 [
              "identificador" => "bib0355"
              "etiqueta" => "35"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:1 [
                            0 => "J&#46;M&#46; Pawlotsky"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1053/j.gastro.2016.04.003"
                      "Revista" => array:6 [
                        "tituloSerie" => "Gastroenterology"
                        "fecha" => "2016"
                        "volumen" => "151"
                        "paginaInicial" => "70"
                        "paginaFinal" => "86"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27080301"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            35 => array:3 [
              "identificador" => "bib0360"
              "etiqueta" => "36"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Expanding consensus in portal hypertension&#58; report of the Baveno VI Consensus Workshop&#58; stratifying risk and individualizing care for portal hypertension"
                      "autores" => array:1 [
                        0 => array:3 [
                          "colaboracion" => "Baveno VI Faculty"
                          "etal" => false
                          "autores" => array:1 [
                            0 => "R&#46; De Franchis"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jhep.2015.05.022"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Hepatol"
                        "fecha" => "2015"
                        "volumen" => "63"
                        "paginaInicial" => "743"
                        "paginaFinal" => "752"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26047908"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
          ]
        ]
      ]
    ]
  ]
  "idiomaDefecto" => "en"
  "url" => "/22548874/0000021800000001/v1_201801040959/S2254887417301285/v1_201801040959/en/main.assets"
  "Apartado" => array:4 [
    "identificador" => "48740"
    "tipo" => "SECCION"
    "en" => array:2 [
      "titulo" => "Reviews"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "en"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/22548874/0000021800000001/v1_201801040959/S2254887417301285/v1_201801040959/en/main.pdf?idApp=WRCEE&text.app=https://revclinesp.es/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2254887417301285?idApp=WRCEE"
]
Article information
ISSN: 22548874
Original language: English
The statistics are updated each day
Year/Month Html Pdf Total
2024 April 1 0 1
2023 March 4 6 10
2018 February 1 0 1
2018 January 1 1 2
2017 December 0 1 1

Follow this link to access the full text of the article

Idiomas
Revista Clínica Española (English Edition)
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?